CURRICULUM VITAE Adel K. El-Naggar, M.D., Ph.D. · CURRICULUM VITAE Adel K. El-Naggar, M.D., Ph.D. PRESENT TITLE AND AFFILIATION Primary Appointment Professor, Department of Pathology,

CV Output

file:///C|/Users/cjohnson5/Desktop/AEN_CompCV_03.05.2014.htm[3/5/2014 4:13:59 PM]

CURRICULUM VITAE

Adel K. El-Naggar, M.D., Ph.D.

PRESENT TITLE AND AFFILIATIONPrimary Appointment

Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas, MD Anderson CancerCenter, Houston, TX

Kenneth D. Muller Professorship, Melanoma Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct AppointmentN/A

CITIZENSHIPUnited States

OFFICE ADDRESSThe University of Texas MD Anderson Cancer Center1515 Holcombe Blvd.,Unit Number: 085Houston, TX 77030Room Number: G1.3561APhone: (713) 792-3109Fax: (713) 745-1105Email: [email protected]

EDUCATIONDegree-Granting Education

Ein-Shams School of Medicine, Cairo, Egypt, MBChB, 1970, M.D.

Ein-Shams School of Medicine, Cairo, Egypt, DMSc, 1973, Clinical Pathology

Department of Immunology, US Naval Research Unit-3 Ein-Shams School of Medicine, Cairo, Egypt, PHD, 1978,Mechanism of Cell-Mediated Immunity in Tuberculous Meningitis

Postgraduate TrainingHouse Officer, Ein-Shams School of Medicine, Cairo, Egypt, 1970-1971

Resident, Clinical Pathology University Hospital, Cairo, Egypt, 1971-1974

Research Fellow, Research Hematology Unit, Ein-Shams School of Medicine, Cairo, Egypt, 1974-1975

Doctoral Fellow, Department of Immunology, US Naval Research Unit - 3, Cairo, Egypt, 1975-1978

Senior Research Fellow, Department of Internal Medicine and Pathology, University of New Mexico, Albuquerque, NM,1978-1980

Research Associate, Department of Microbiology, Vanderbilt University School of Medicine, Nashville, TN, 1981-1982

Chief Resident, Institute of Pathology, Case Western Reserve University and University Hospital of Cleveland, Cleveland,OH, 1982-1986

Fellow, Department of Pathology, The University of Texas Cancer Center, M.D.Anderson Hospital and Tumor Institute,Houston, TX, 1986-1987

CREDENTIALSBoard Certification

Anatomic and Clinical Pathology, 1988

LicensuresActive

Medical Board, TX, H1434, 1985

InactiveN/A

EXPERIENCE/SERVICE

CV Output


Academic AppointmentsInstructor in Clinical Pathology, Ein-Shams School of Medicine, Cairo, Egypt, 1974-1975

Guest Scientist, Immunopathology Department, U.S. Naval Medical Research Unit No. 3 (NAMRU 3), Cairo, Egypt, 1975-1978

Assistant Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas, M.D. AndersonCancer Center, Houston, TX, 1987-1991

Associate Professor and Pathologist, Director of Flow Cytometry Section, Department of Pathology, Pathology, TheUniversity of Texas, M.D. Anderson Cancer Center, Houston, TX, 1991-1995

Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas, MD Anderson CancerCenter, Houston, TX, 1995-present

Adjunct Professor, Department of Pathology, Ein-Shams University, Cairo, Egypt, 1996-present

Administrative Appointments/ResponsibilitiesHead and Neck Section Chief, Cell Kinetric and Flow Cytometry, Department of Pathology, Pathology, The University ofTexas M. D. Anderson Cancer Center, Houston, TX, 1987-1998

Section Chief, Department of Pathology, Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX,1998-present

Director of the Head and Neck Pathology Fellowship Program, Department of Pathology, Pathology, The University ofTexas MD Anderson Cancer Center, Houston, TX, 2002-present

Other Appointments/ResponsibilitiesOrganizing Committee, The International forum for Head and Neck Cancer Research, McLean, VA, 1997-1998

Oncology Group, Head and Neck, American College of Surgeons - ECOSOG, Chicago, IL, 1998-2006

Head and Neck Committee, American College of Radiology Imaging Network (ACRIN), Philadelphia, PA, 1998-present

External Advisor, Molecular Genetic Center, Kuwait City, Kuwait, 1998-present

Sterring Committee Member NCI, Head and Neck Intergroup, Bethesda, MD, 1998-present

Pathology and Tissue Banking Committee, (RTOG) Radiation Therapy Oncology Group, Philadelphia, 2000-present

Member of Head and Neck Surgery Committee, (RTOG) Radiation Therapy Oncology Group, Philadelphia, PA, 2000-present

Member, Head and Neck Executive Committee, (RTOG) Radiation Therapy Oncology Group, Philadelphia, 2001-present

Chair, Correlative Science and Pathology, (SWOG) Southwest Oncology Group, Bethesda, MD, 2003-2007

External Advisory Board, Head and Neck SPORE Program, University of Pittsburgh, Pittsburgh, PA, 2004-present

External Advisory Board, The Lung PO1 Program, Emory University, Atlanta, GA, 2004-present

Co-Chair, Scientific Session, The 6th International HN Cancer Meeting, Washington, DC, 2004

Co-Chair , Molecular Genetic in Solid Tumor, The 6th International Molecular Biology of Cancer, Crete, Greece, 2004

Organizing Committee, Head and Neck Research Workshop, Bethesda, MD, 2006

Director, Rare Disease Consortium, Philadelphia, PA, 2008-present

Member, American College of Radiology Imaging Network (ACRIN), 2008

Member of the Organizing Committee, 7th International Conference of Head and Neck Cancer, San Francisco, CA, 2008

Endowed PositionsKenneth D. Muller Professorship, The University of Texas MD Anderson Cancer Center, Houston, TX, 1997-present

Co-Chair of the 3rd Salivary Gland Workshop, The University of Texas MD Anderson Cancer Center, Washington, DC,5/2012

ConsultantshipsCDMRP Lung Cancer Research Program, Panel member, 8/2009-present

Military or Other Governmental ServiceHematology Laboratory, Army Central Laboratories, Hematopathologist, 1975-1976

Institutional Committee ActivitiesMedical Records, Member, 1991-1993

Medical Practice, Member, 1993-1996

CV Output


Promotion Committee, Member, 1994-1999

Institutional Research Direction Committee, Member, 1995-1996

Planning Committee, for the Institutional Research Forum, Member, 1997-1998

Institutional Tissue Procurement Facility, Co-Director, 1997-1999

Planning Committee for Physician Scientist Program, Member, 1998-1999

Committee on Export of Export of Patient Materials for Commercial Use, Member, 1998-1999

Search Committee, Chairman of Hematopathology Department, 11/1999-4/2000

Fellowship Program Committee, Member, 2000-present

Search Committee, Chairman, Head and Neck Surgery Department, 2002-2003

Search Committee, Chairman of Endocrine Neoplasia and Hormonal Disorders Department, 2003-2004

PGE Committee, Member, 2005

Member of the Department of Pathology Executive Committee, Member, 2007-present

Institutional Graduate Medical Education (GMEC), Member, 2007-present

GME Institutional Review Subcommittee, Member, 2007-present

HONORS AND AWARDSLetter of Merits, US Naval Medical Research, Unit - 3 (NAMRU - 3), 1978

The Mediterranean Society of Tumor Markers, Recognition Award, 1994

The B. Rothschild Senior Research Scholarship, Curie Institute, 1997-1998

Kenneth D. Muller Endowed Professorship in Cancer Research, 1998-present

The American Head and Neck Surgeons, Presidential Citation, 2007

The American Head and Neck Surgeons, Hayes-Martin Memorial Lectureship, 2010

Foreign Member of the The Royal Society of Arts and Sciences in Gothenburg, Kungl. Vetenskaps- och Vitterhets-Samhället iGöteborg, 2012-present

RESEARCHGrants and Contracts

FundedCollaborator, 0.15 months, Role of p53 Missense Mutations on Tumorigenesis in Vivo, 5 R01 CA082577 13, NIH/NCI,9/1/1999-12/31/2014 ($420,101/year)

Core Leader, 15%, MD Anderson Cancer Center Head and Neck SPORE(PC-C1), 5 P50 CA097007 09, NIH/NCI,9/30/2002-7/31/2014, $1,459,502 ($992,629/year)

Collaborator, 0.08 months, Genotypes and Phenotypes of Apoptosis and Risk of Head and Neck Cancer, 5 R01CA131274 04, NIH/NCI, PI - Qingyi Wei, 3/2/2009-1/31/2014, $625,911 ($1,831,158/year)

Principal Investigator, 1.17 months, Salivary Gland Tumor Biorepository, HHSN26820090039C 02, NIH/NIDCR,8/10/2009-8/9/2014, $518,140 ($1,624,291/year)

Principal Investigator, 0.8 months, Molecular and Epidemiologic Characterization of Salivary Gland Carcinomas(PP-1), 5U01 DE019765 03, NIH/NIDCR, 9/20/2009-5/31/2014 ($1,019,530/year)

Principal Investigator, 1.61 months, Molecular and Epidemiologic Characterization of Salivary Gland Carcinomas(PP-4),5 U01 DE019765 03, NIH/NIDCR, 9/20/2009-5/31/2014 ($434,233/year)

Collaborator, 0.11 months, Targeting c-Src kinases in Head and Neck Cancer, 5 R01 CA143369 02, NIH/NCI, 1/1/2010-12/31/2014 ($489,341/year)

Principal Investigator, 0.6 months, ARRA: The Cancer Genome Atlas: M. D. Anderson Head and Neck Collaboration,HHSN2612010000471 01, NIH/NCI, 6/10/2010-9/30/2014 ($879,122/year)

Co-Investigator, Multi-modal Opical Imaging System for Eary Detection of Oral Canc, RP100932 03, Cancer Prevention& Research Institute of Texas (CPRIT), 4/1/2012-3/31/2013 ($527,254/year)

PendingCollaborator, 0.12 months, Cytokine Status as Predictors of Patient-Reported Symptoms in Head & Neck Cancers, R01Grant Tracking #11314302, NIH/NIDCR, PI - Guojun Li, 9/1/2013-8/31/2018, $3,945,564 ($2,489,351/year)

Collaborator, 0.12 months, miRNA Signatures as Prognostic Biomarkers of HPV-associated Oropharyngeal Cancer, R01

CV Output


Grant Tracking #11316393, NIH/NCI, PI - Guojun Li, 9/1/2013-8/31/2018, $3,942,073 ($2,487,169/year)

Co-Investigator, 20%, Function and targeting of alphaV integrins in metastatic skin cancer., N/A - new submission, ElsaU. Pardee Foundation, PI - Caulin, Carlos, 7/1/2014-6/30/2015, $150,000 ($150,000/year)

Co-Investigator, 0.12 months, Role of Alpha-v Integrins in Skin Cancer Progression, N/A - new submission, NIH/NCI, PI- Carlos Caulin, 7/1/2014-6/30/2019, $1,250,000 ($250,000/year)

Co-Investigator, 2%, Epithelial integrins that promote skin cancer progression and metastasis, RP140346, CancerPrevention & Research Institute of Texas (CPRIT), PI - Caulin, Carlos, 8/31/2014-8/30/2017, $855,000 ($285,000/year)

OtherN/A

CompletedCollaborator, 1%, A Pathway of Tumor Suppressor, 5 R01 CA47296 21, NIH/NCI, PI - Guillermina Lozano, 7/1/1988-5/31/2011, $717,906 ($717,906/year)

Collaborator, 2%, A Mutational Model for Childhood Cancer (PC-B), 5 PO1 CA03436 21, NIH/NCI, PI - Louise C.Strong, 8/1/1997-4/30/2011, $1,229,320 ($1,229,320/year)

Collaborator, 0.6 months, Extension of Radiotherapy Research(PP-2), 5 P01 CA006294 44, NIH/NCI, PI - Michael D.Story, 3/6/1998-5/31/2011, $823,871 ($832,540/year)

Collaborator, 5%, The BESCT (Biology, Education, Screening, Chemoprevention, and Treatment) Lung Cancer Program(PP-2), DAMD17-01-1-0689 05, Fed, PI - Waun K. Hong, 3/15/2001-3/15/2009, $1,779,140 ($1,779,140/year)

Collaborator, 5%, The BESCT (Biology, Education, Screening, Chemoprevention, and Treatment) Lung Cancer Program(PP-3), DAMD17-01-1-0689 05, Fed, PI - Ho-Young Lee, 3/15/2001-3/15/2009, $2,201,066 ($2,201,066/year)

Collaborator, 10%, The Impact of Smoking on Lung Cancer Chemoprevention (PP-1), 5 PO1 CA091844 05, NIH/NCI, PI- Jonathan M. Kurie, 8/20/2001-7/31/2008, $1,944,673 ($1,944,673/year)

Collaborator, 2%, The Impact of Smoking on Lung Cancer Chemoprevention (PP-3), 5 PO1 CA091844 05, NIH/NCI, PI- Li Mao, 8/20/2001-7/31/2008, $1,222,941 ($1,222,941/year)

Collaborator, 5%, MD Anderson Cancer Center SPORE in Head and Neck, 3 P50 CA097007 05 S2, NIH/NCI, PI - ScottM. Lippman, 9/30/2002-7/31/2008, $750,000 ($750,000/year)

Principal Investigator, 15%, MD Anderson Cancer Center SPORE in Head and Neck Bridge Funding, 3 P50 CA09700705 S1, NIH/NCI, 9/30/2002-7/31/2008, $53,008 ($53,008/year)

Collaborator, Fluorescence Spectroscopy to Detect Oral Neoplasia, 5 RO1 CA095604-04, NIH/NCI, PI - AnnGillenwater, M.D., 5/15/2003-4/3/2008, $1,126,354

Collaborator, 5%, Characterization of Leiomyosarcoma and GIST by Genomics, 5 RO1 CA098570 04, NIH/NCI, PI - WeiZhang, 7/1/2003-6/30/2009, $1,246,906

Collaborator, 5%, MD Anderson Gynecologic SPORE for Uterine Cancer (PC-B), 5 P50 CA09828 05, NIH/NCI, PI -Russell Broaddus, 9/1/2003-8/31/2009, $799,798

Collaborator, 10%, VITAL (Vanguard Investigations of Therapeutic Approaches to Lung Cancer) (PC-C), W81XWH-04-1-0142 05, Fed, PI - Ignacio I Wistuba, 12/15/2003-1/14/2010, $860,373

Collaborator, 2%, Novel Strategy for Lung Cancer Treatment using IGFBP-3, RSG-04-082-01-TBE 04, OPFR, PI - Ho-Young Lee, 1/1/2004-12/31/2008, $720,000

Collaborator, 2%, Novel Strategy for Lung Cancer Using IGFBP-2, 5 RO1 CA100816 04, NIH/NCI, PI - Ho-Young Lee,5/1/2004-4/30/2009, $971,907

Collaborator, 1%, U10 Full Member Application Alliliated with SWOG, 5 U10 CA105409 05, NIH/NCI, PI - Roy S. Herbst,7/26/2004-12/31/2009, $905,028

Principal Investigator, 10%, Molecular-Based Therapy for Oral cancer Prevention (PC-C2), 5 PO1 CA106451 05,NIH/NCI, 8/1/2004-7/31/2010, $264,036

Collaborator, 1.2 months, Molecular-Based Therapy for Oral Cancer Prevention (PC-C1), 5 P01 CA106451 06,NIH/NCI, PI - Mary J. Johansen, 8/1/2004-7/31/2011, $620,576 ($694,375/year)

Collaborator, 2%, Novel Strategy for Lung Cancer Chemoprevention and Treatment Using Deguelin, a Natural Product,5 R01 CA109520 05, NIH/NCI, PI - Ho-Young Lee, 9/1/2004-6/30/2009, $1,206,716

Collaborator, 5%, Multispectral Imaging for Oral Cancer Detection, 5 R21 DE016485 02, NIH/NCI, PI - Ann Gillenwater,9/23/2004-6/30/2008, $328,061

Collaborator, 2%, Polarization Spectroscopy and Imaging of Pre-Cancer (PC1), 5 R01 EB003540 04, NIH/NCI, PI -

CV Output


Konstantin V. Sokolov, 5/11/2005-2/28/2010, $771,692

Co-Investigator, 0.12 months, Cytokine Variants as Predictors of HPV-16 Status & Outcome of Oropharyngeal Cancer,R03CA135679, NIH/NCI, 7/1/2008-8/31/2010 ($50,000/year)

Collaborator, 0.15 months, ARRA: Comprehensive Analysis of Genetic Alterations in Oral Cancer, 5 RC2 DE020958 02,NIH/NIDCR, 9/25/2009-8/31/2012 ($2,398,656/year)

Collaborator, 0.39 months, A single nucleotide polymorphism in Mdm2 regulates p53 activity, RP100535 03, CancerPrevention & Research Institute of Texas (CPRIT), 5/1/2010-4/30/2013 ($263,250/year)

Principal Investigator, 1.2 months, TCGA Head & Neck and Thyroid, HHSN261201000471, NIH/NCI, 6/10/2010-6/9/2012, $1,007,250 ($1,007,250/year)

Not FundedN/A

ProtocolsFunded

N/A

UnfundedN/A

Patents and Technology LicensesPatents

N/A

Technology LicensesN/A

Grant Reviewer/Service on Study SectionsLung Research Panel, Member, 2009

PUBLICATIONSPeer-Reviewed Original Research Articles

1. Ibrahim WN, Kamel K, Selim O, Azim A, Gaballah MF, Sabry F, El-Naggar AK, Koerman K. Hereditary blood factorsand anthropometry of inhabitants of the Egyptian Siwa Oasis. Hum Biol 46:57-68, 1974.

2. Kamel K, Umar M, Ibrahim W, Mansour A, Gaballah F, Selim O, Azim A, Hamza S, Sabry F, Moafy N, El-Naggar AK,Hoerman K. Anthropological studies among Libyans. Erythrocyte genetic factors, serum haptoglobin phenotypes andanthropometry. Am J Phys Anthropol 43:103-111, 1975.

3. Reiner NE, Kamel R, Higashi GI, El-Naggar AK, Aguib M, Ellner JJ, Mahmoud AA. Concurrent responses of peripheralblood and splenic mononuclear cells to antigenic and mitogenic stimulation in human hepatosplenic schistosomiasis. JInfect Dis 140:162-168, 1979.

4. El-Naggar AK, Van Epps DE, Williams RC, Jr. Human-B and T-lymphocyte locomotion in response to casein, C5a, andf-met-leu-phe. Cell Immunol 56:365-373, 1980.

5. El-Naggar AK, Van Epps D, Williams RC Jr. Effect of culturing on the human lymphocyte locomotion response tocasein, Cda and f-Met-Leu-Phe. Cell Immunol 80:43-49, 1981.

6. El-Naggar AK, Higashi GI. Tuberculous meningitis: E-rosette-forming T lymphocytes in cerebrospinal fluid. Neurology31:610-612, 1981.

7. El-Naggar AK, Van Epps DE, Williams RC, Jr. A human lymphocyte chemotactic factor produced by the mixedlymphocyte reaction. J Lab Clin Med 100:558-565, 1982.

8. El-Naggar AK, Higashi GI. Cell-mediated immunity in Tuberculous meningitis: Delayed-type hypersensitivity, T-lymphocytes and blastogenic transformation responses. J Clin Lab Immunol 8:37-42, 1982.

9. El Naggar AK, Colley DG. Modulation of schistosoma mansoni egg-induced granuloma formation. II. Soluble suppressoractivity from lymphoid cels during chronic infection. Cell Immunol 72:151-156, 1982.

10. Van Epps DE, El-Naggar AK, Ochs HD. Abnormalities of lymphocyte locomotion in immunodeficiency disease. Clin ExpImmunol 53:678-688, 1983.

11. El-Naggar AK, Abdul-Karim FW, Marshalleck JJ, Sorensen K. Fine-needle aspiration of fibromatosis of the breast.Diagn Cytopathol 3:320-322, 1987.

12. Ro JY, Ayala AG, El-Naggar AK. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am JSurg Pathol 11:668-73, 1987.

13. Ro JY, Ayala AG, El-Naggar AK, Wishnow KI. Seminal vesicle involvement by in situ and invasive transitional cellcarcinoma of the bladder. Am J Surg Pathol 11:951-958, 1987.

14. El-Naggar AK, Batsakis JG, Kessler S. Benign metastatic mixed tumours or unrecognized salivary carcinomas? JLaryngol Otol 102:810-812, 1988.

CV Output


15. El-Naggar AK, Batsakis JG, Luna MA, Hickey RC. Hurthle cell tumors of the thyroid. A flow cytometric DNA analysis.Arch Otolaryngol Head Neck Surg 114:520-521, 1988.

16. Ro JY, El-Naggar AK, Ayala AG, Mody DR, Ordonez NG. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol 12:453-460, 1988.

17. Grignon DJ, Ayala AG, El-Naggar AK, Wishnow KI, Ro JY, Swanson DA, McLemore D, Giacco GG, Guinee VF. Renalcell carcinoma. A clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 64:2133-2140, 11/1989.

18. El-Naggar AK, Ro JY, Ayala AG, Hinchey WW, Abdul-Karim FW, Batsakis JG. Angiomatoid malignant fibroushistiocytoma: flow cytometric DNA analysis of six cases. J Surg Oncol 40:201-204, 1989.

19. Batsakis JG, EL-Naggar AK. Basaloid-squamous carcinomas of the upper aerodigestive tracts. Ann Otol RhinolLaryngol 98:919-920, 1989.

20. Ro JS, El-Naggar AK, Ro JY, Blick M, Frye D, Fraschini G, Fritsche H, Hortobagyi G. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49:6941-6944, 1989.

21. Grignon DJ, El-Naggar AK, Ro JY, Johnson DE, Ayala AG. Deoxyribonucleic acid flow cytometry on primaryadenocarcinoma of the bladder: an analysis of 36 cases. J Urol 142:1206-1210, 1989.

22. El-Naggar AK, Batsakis JG, Luna MA, Goepfert H, Tortoledo ME. DNA content and proliferative activity ofmyoepitheliomas. J Laryngol Otol 103:1192-1197, 1989.

23. Grignon DJ, El-Naggar AK, Green LK, Ayala AG, Ro JY, Swanson DA, Troncoso P, McLemore D, Giacco GG, GuineeVF. DNA flow cytometry as a predictor of outcome of stage I renal cell carcinoma. Cancer 63:1161-1165, 1989.

24. El-Naggar AK, Ro JY, McLemore D, Garnsey L, Ordonez N, MacKay B. Gastrointestinal stromal tumors: DNA flow-cytometric study of 58 patients with at least five years of follow-up. Mod Pathol 2:511-515, 1989.

25. Batsakis JG, Regezi JA, Luna MA, El-Naggar AK. Histogenesis of salivary gland neoplasms: a postulate with prognosticimplications. J Laryngol Otol 103:939-944, 1989.

26. El-Naggar AK, Ro JY, Ayala AG, Ward R, Ordonez NG. Localized fibrous tumor of the serosal cavities.Immunohistochemical, electron-microscopic, and flow-cytometric DNA study. Am J Clin Pathol 92:561-565, 1989.

27. Weber RS, Palmer JM, El-Naggar AK, McNeese MD, Guillamondegui OM, Byers RM. Minor salivary gland tumors ofthe lip and buccal mucosa. Laryngoscope 99:6-9, 1989.

28. Rutledge ML, Silva EG, McLemore D, El-Naggar AK. Serous surface carcinoma of the ovary and peritoneum. A flowcytometric study. Pathol Annu 24:227-235, 1989.

29. Robey SS, Silva EG, Gershenson DM, McLemore D, El-Naggar AK, Ordonez NG. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 63:839-847, 1989.

30. Shetlar DJ, Font RL, Ordonez N, El-Naggar AK, Boniuk M. A clinicopathologic study of three carcinoid tumorsmetastatic to the orbit. Immunohistochemical, ultrastructural, and DNA flow cytometric studies. Ophthalmology 97:257-264, 1990.

31. El-Naggar AK, Batsakis JG, Teague K, Giacco G, Guinee VF, Swanson D. Acridine orange flow cytometric analysis ofrenal cell carcinoma. Clinicopathologic implications of RNA content. Am J Pathol 137:275-280, 1990.

32. Ro JY, Ayala AG, El-Naggar AK, Grignon DJ, Hogan SF, Howard DR. Angiomyolipoma of kidney with lymph nodeinvolvement. DNA flow cytometric analysis. Arch Pathol Lab Med 114:65-67, 1990.

33. Luna MA, El-Naggar AK, Parichatikanond P, Weber RS, Batsakis JG. Basaloid squamous carcinoma of the upperaerodigestive tract. Clinicopathologic and DNA flow cytometric analysis. Cancer 66:537-542, 1990.

34. Ro JY, El-Naggar AK, Holmes FA, Close D, Hortobagyi GN. Brain Metastasis initial presentation of breast cancer: DNAflow cytometric comparison of two sites. . Breast 3:35-38, 1990.

35. Tornos C, Silva E, El-Naggar AK, Pritzker KP. Calcium oxalate crystals in breast biopsies. The missingmicrocalcifications. Am J Surg Pathol 14:961-968, 1990.

36. Robe-Cafferty, El-Naggar AK, Grignon D, Cleary K, Ro JY. Clinicopathologic and DNA flow cytometric study of stage-Bcolon and rectal carcinomas. . Mod Pathol 3:261-266, 1990.

37. El-Naggar AK, Ordonez NG, McLemore D, Schultz P, Hickey RC, Samaan N. Clinicopathologic and flow cytometricDNA study of medullary thyroid carcinoma. Surgery 108:981-985, 1990.

38. El-Naggar AK, Ro JY, McLemore D, Garnsy L. DNA content and proliferative activity of cystosarcoma phyllodes of thebreast. Potential prognostic significance. Am J Clin Pathol 93:480-485, 1990.

39. El-Naggar AK, Batsakis JG, Luna MA, McLemore D, Byers RM. DNA flow cytometry of acinic cell carcinomas of majorsalivary glands. J Laryngol Otol 104:410-416, 1990.

40. Corkill ME, Sneige N, Fanning T, El-Naggar AK. Fine-needle aspiration cytology and flow cytometry of intracysticpapillary carcinoma of breast. Am J Clin Pathol 94:673-680, 1990.

41. Sahin AA, Ro JY, El-Naggar AK, Lee JS, Ayala AG, Teague K, Hong WK. Flow cytometric analysis of the DNA contentof non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung.Cancer 65:530-537, 1990.

42. Luna MA, El-Naggar AK, Batsakis JG, Weber RS, Garnsey LA, Goepfert H. Flow cytometric DNA content of adenoidcystic carcinoma of submandibular gland. Correlation of histologic features and prognosis. Arch Otolaryngol Head NeckSurg 116:1291-1296, 1990.

43. Sara AS, Ayala AG, El-Naggar AK, Ro JY, Raymond AK, Murray JA. Giant cell tumor of bone. A clinicopathologic and

CV Output


DNA flow cytometric analysis. Cancer 66:2186-2190, 1990.44. Batsakis JG, Luna MA, El-Naggar AK. Histopathologic grading of salivary gland neoplasms: II. Acinic cell carcinomas.

Ann Otol Rhinol Laryngol 99:929-933, 1990.45. Batsakis JG, Luna MA, El-Naggar AK. Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic

carcinomas. Ann Otol Rhinol Laryngol 99:1007-1009, 1990.46. Ro JY, Ayala AG, Tetu B, Ordonez NG, El-Naggar AK, Grignon DJ, Mackay B. Merkel cell carcinoma metastatic to the

testis. Am J Clin Pathol 94:384-389, 1990.47. McLemore DD, El Naggar AK, Stephens LC, Jardine JH. Modified methodology to improve flow cytometric DNA

histograms from paraffin-embedded material. Stain Technol 65:279-291, 1990.48. Sahin AA, Ro JY, Ordonez NG, Luna MA, El-Naggar AK, Goepfert H, Ayala AG. Myofibroblastoma of the tongue. An

immunohistochemical, ultrastructural, and flow cytometric study. Am J Clin Pathol 94:773-777, 1990.49. Ballance WA, Ro JY, El-Naggar AK, Grignon DJ, Ayala AG, Romsdahl MG. Pleomorphic adenoma (benign mixed

tumor) of the breast. An immunohistochemical, flow cytometric, and ultrastructural study and review of the literature.Am J Clin Pathol 93:795-801, 1990.

50. Loose JH, El-Naggar AK, Ro JY, Huang WL, McMurtrey MJ, Ayala AG. Primary osteosarcoma of the lung. Report oftwo cases and review of the literature. J Thorac Cardiovasc Surg 100:867-873, 1990.

51. Grignon DJ, Ayala AG, Ro JY, El-Naggar AK, Papadopoulos NJ. Primary sarcomas of the kidney. A clinicopathologicand DNA flow cytometric study of 17 cases. Cancer 65:1611-1168, 1990.

52. Batsakis JG, El-Naggar AK. Sebaceous lesions of salivary glands and oral cavity. Ann Otol Rhinol Laryngol 99:416-418, 1990.

53. El-Naggar AK, Mackay B, Sneige N, Batsakis JG. Stromal neoplasms of the breast: a comparative flow cytometricstudy. J Surg Oncol 44:151-156, 1990.

54. El-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, Ballance WW, Garnsey L, Ro JY, Batsakis JG. Synovialsarcoma. A DNA flow cytometric study. Cancer 65:2295-2300, 1990.

55. Batsakis JG, El-Naggar AK. Warthin's tumor. Ann Otol Rhinol Laryngol 99:588-591, 1990.56. Ordonez NG, El-Naggar AK, Hickey RC, Samaan NA. Anaplastic thyroid carcinoma. Immunocytochemical study of 32

cases. Am J Clin Pathol 96:15-24, 1991.57. Batsakis JG, Luna MA, El-Naggar AK. Basaloid monomorphic adenomas. Ann Otol Rhinol Laryngol 100:687-690, 1991.58. Frauenhoffer EE, Ro JY, El-Naggar AK, Ordonez NG, Ayala AG. Clear cell cribriform hyperplasia of the prostate.

Immunohistochemical and DNA flow cytometric study. Am J Clin Pathol 95:446-453, 1991.59. El-Naggar AK, Ordonez NG, Sara A, McLemore D, Batsakis JG. Clear cell sarcomas and metastatic soft tissue

melanomas. A flow cytometric comparison and prognostic implications. Cancer 67:2173-2179, 1991.60. Sneige N, Dekmezian R, El-Naggar AK, Manning J. Cytomorphologic, immunocytochemical, and nucleic acid flow

cytometric study of 50 lymph nodes by fine-needle aspiration. Comparison with results obtained by subsequentexcisional biopsy. Cancer 67:1003-1007, 1991.

61. Ayala, Ro JY, El-Naggar AK:. DNA flow cytometry in prostatic carcinoma. Pathologica 23:137-138, 1991.62. Sella, El-Naggar AK, Ro JY, et al. DNA ploidy in mature testicular teratoma. J Urol 146:1025-1028, 1991.63. El-Naggar AK, Ordonez NG, Garnsey L, Batsakis JG. Epithelioid pleural mesotheliomas and pulmonary

adenocarcinomas: a comparative DNA flow cytometric study. Hum Pathol 22:972-978, 1991.64. Shabb N, Katz R, Ordonez N, Goodacre A, Hirsch-Ginsberg C, El-Naggar AK. Fine-needle aspiration evaluation of

lymphoproliferative lesions in human immunodeficiency virus-positive patients. A multiparameter approach. Cancer67:1008-1018, 1991.

65. Ro JY, Sahin AA, El-Naggar AK, Ordonez NG, Mackay B, Llamas LL, Ayala AG. Intraluminal crystalloids in strumaovarii. Immunohistochemical, DNA flow cytometric, and ultrastructural study. Arch Pathol Lab Med 115:145-149, 1991.

66. Sara A, El-Naggar AK. Intratumoral DNA content variability. A study of non-small cell lung cancer. Am J Clin Pathol96:311-317, 1991.

67. Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Ki-67immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68:549-557, 1991.

68. El-Naggar AK, Batsakis JG, Vassilopoulou-Sellin R, Ordonez NG, Luna MA. Medullary (thyroid) carcinoma-likecarcinoids of the larynx. J Laryngol Otol 105:683-686, 1991.

69. El-Naggar AK, Evans DB, Mackay B. Oncocytic adrenal cortical carcinoma. Ultrastruct Pathol 15:549-556, 1991.70. El-Naggar AK, Ordonez NG, Batsakis JG. Parotid gland plasmacytoma with crystalline deposits. Oral Surg Oral Med

Oral Pathol 71:206-208, 1991.71. Sahin, Ro JY, El-Naggar AK, Ordonez NG, Babaian RJ, Ayala AG. Pseudosarcomatous fibromyxoid tumor of the

prostate: A case report with immunohistochemical, electron microscopic, and DNA flow cytometric analysis. Am J ClinPathol 96:253-258, 1991.

72. Luna MA, Batsakis JG, El-Naggar AK. Salivary gland tumors in children. Ann Otol Rhinol Laryngol 100:869-871, 1991.73. El-Naggar AK, Ro JY, Sella A, Ayala AG. Simultaneous renal and transitional cell carcinomas in same kidney with

subsequent lymph node metastasis: DNA flow cytometric study. Urology 38:585-588, 1991.

CV Output


74. El-Naggar AK, Batsakis JG, Teague K, Garnsey L, Barlogie B. Single- and double-stranded RNA measurements byflow cytometry in solid neoplasms. Cytometry 12:330-335, 1991.

75. Batsakis JG, El-Naggar AK. Terminal duct adenocarcinomas of salivary tissues. Ann Otol Rhinol Laryngol 100:251-253,1991.

76. Ro JY, Dexeus FH, El-Naggar AK, Ayala AG. Testicular germ cell tumors. Clinically relevant pathologic findings. PatholAnnu 26:59-87, 1991.

77. Sahin AA, Ro JY, El-Naggar AK, Wilson PL, Teague K, Blick M, Ayala AG. Tumor proliferative fraction in solidmalignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations. Am J ClinPathol 96:512-519, 1991.

78. El-Naggar AK, Ballance W, Karim FW, Ordonez NG, McLemore D, Giacco GG, Batsakis JG. Typical and atypicalbronchopulmonary carcinoids. A clinicopathologic and flow cytometric study. Am J Clin Pathol 95:828-834, 1991.

79. El-Naggar AK, Abdul-Karim FW, Silva E, McLemore D, Garnsey L. Uterine stromal neoplasms: a clinicopathologic andDNA flow cytometric correlation. Hum Pathol 22:897-903, 1991.

80. Frauenhoffer EE, Ro JY, Silva EG, El-Naggar AK. Well-differentiated serous ovarian carcinoma presenting as a breastmass: a case report and flow cytometric DNA study. Int J Gynecol Pathol 10:79-87, 1991.

81. Batsakis JG, El-Naggar AK, Luna MA. Epithelial-myoepithelial carcinoma of salivary glands. Ann Otol Rhinol Laryngol101:540-542, 6/1992.

82. Batsakis JG, El-Naggar AK, Luna MA. "Adenocarcinoma, not otherwise specified": a diminishing group of salivarycarcinomas. Ann Otol Rhinol Laryngol 101:102-104, 1992.

83. Shahab I, Fraire AE, Greenberg SD, Mawad J, El-Naggar AK:. A clinically aggressive, solitary fibrous mediastinal tumorexhibiting a diploid stemline pattern. . Houston Medicine 8:23-26, 1992.

84. Tornos C, Silva EG, El-Naggar AK, Burke TW. Aggressive stage I grade 1 endometrial carcinoma. Cancer 70:790-798,1992.

85. Shin DM, El-Naggar AK, Putnam JB, Komaki R, Hong WK. Case reports: Pathologic remission of invasive thymomaafter induction chemotherapy. The Cancer Bulletin 44:346-348, 1992.

86. El-Naggar AK, Pathak S. Cytogenetic and corresponding flow cytometric DNA analysis of renal cell neoplasms.Anticancer Res 12:1491-1500, 1992.

87. Abdul-Karim FW, El-Naggar AK, Joyce MJ, Makley JT, Carter JR. Diffuse and localized tenosynovial giant cell tumorand pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis. Hum Pathol 23:729-735,1992.

88. El-Naggar AK, Ro JY, McLemore D, Ayala AG, Batsakis JG. DNA ploidy in testicular germ cell neoplasms. Histogeneticand clinical implications. Am J Surg Pathol 16:611-618, 1992.

89. El-Naggar AK, Garcia GM. Epithelioid sarcoma. Flow cytometric study of DNA content and regional DNA heterogeneity.Cancer 69:1721-1728, 1992.

90. Misra, Parihar AL, El-Naggar AK. Exclusion of residual angiosarcoma of the breast by MRI. Breast Cancer Res Treat21:221-224, 1992.

91. Jacobs JC, Katz RL, Shabb N, El-Naggar AK, Ordonez NG, Pugh W. Fine needle aspiration of lymphoblasticlymphoma. A multiparameter diagnostic approach. Acta Cytol 36:887-894, 1992.

92. Batsakis JG, Sneige N, El-Naggar AK. Fine-needle aspiration of salivary glands: its utility and tissue effects. Ann OtolRhinol Laryngol 101:185-188, 1992.

93. Mulhollan TJ, Ro JY, El-Naggar AK, Sahin AA, Ayala AG. Granular cell tumor of the biliary tree. Am J Surg Pathol16:204-206, 1992.

94. El-Naggar AK, Lopez-Varela V, Luna MA, Weber R, Batsakis JG. Intratumoral DNA content heterogeneity in laryngealsquamous carcinoma. Arch Otolaryngol Head Neck Surg 2:169-173, 1992.

95. Voravud N, El-Naggar AK, Balch CM, Theriault RL. Metastatic lobular breast carcinoma simulating primary coloncancer. Am J Clin Oncol 15:365-369, 1992.

96. Batsakis JG, El-Naggar AK, Luna MA. Neuroendocrine tumors of larynx. Ann Otol Rhinol Laryngol 101:710-704, 1992.97. Rodriguez-Peralto JL, El-Naggar AK. Neurothekeoma of the oral cavity: case report and review of the literature. J Oral

Maxillofac Surg 50:1224-1226, 1992.98. Carrillo R, El-Naggar AK, Luna MA, Rodriguez-Peralto JL, Batsakis JG. Nucleolar organizer regions (NORs) and

myoepitheliomas: a comparison with DNA content and clinical course. J Laryngol Otol 106:616-620, 1992.99. Carrillo, Rodreguez-Peralto JL, Batsakis JG, El-Naggar AK. Pathology in focus: Primary hemangiopericytomas of the

parotid gland. . J Laryngology & Otology 106:659-661, 1992.100. del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, El-Naggar AK, Deisseroth A.

Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood 79:2717-2720,1992.

101. Graham RA, Teague K, McLemore D, Cleary K, El-Naggar AK. Regional DNA content heterogeneity in colonicadenocarcinoma: prognostic significance in patients with liver metastases. J Surg Oncol 50:228-232, 1992.

102. Hartwick RW, El-Naggar AK, Ro JY, Srigley JR, McLemore DD, Jones EC, Grignon DJ, Thomas MJ, Ayala AG. Renaloncocytoma and granular renal cell carcinoma. A comparative clinicopathologic and DNA flow cytometric study. Am J

CV Output


Clin Pathol 98:587-593, 1992.103. Batsakis JG, El-Naggar AK. Rhinoscleroma and rhinosporidiosis. Ann Otol Rhinol Laryngol 101:879-882, 1992.104. El-Naggar AK, Batsakis JG, Garcia GM, Luna ML, Goepfert H. Sinonasal hemangiopericytomas. A clinicopathologic and

DNA content study. Arch Otolaryngol Head Neck Surg 118:134-137, 1992.105. Gomez R, El-Naggar AK, Byers RM, Garnsey L, Luna MA, Batsakis JG. Squamous carcinoma of oral tongue:

prognostic significance of flow-cytometric DNA content. Mod Pathol 5:141-145, 1992.106. Carrillo R, El-Naggar AK, Rodriguez-Peralto JL, Batsakis JG. Synovial sarcoma of the tongue: case report and review

of the literature. J Oral Maxillofac Surg 50:904-906, 1992.107. Pollack A, El-Naggar AK, Cox JD, Ro JY, Sahin A, Komaki R. Thymoma. The prognostic significance of flow cytometric

DNA analysis. Cancer 69:1702-1709, 1992.108. Klijanienko J, El-Naggar A, Ponzio-Prion A, Marandas P, Micheau C, Caillaud JM. Basaloid squamous carcinoma of the

head and neck. Immunohistochemical comparison with adenoid cystic carcinoma and squamous cell carcinoma. ArchOtolaryngol Head Neck Surg 119:887-890, 1993.

109. Ordonez NG, Mackay B, El-Naggar AK, Bannayan GA, Duncan J. Clear cell carcinoid tumour of the stomach.Histopathology 22:190-193, 1993.

110. Wojcik EM, Katz RL, Johnston DA, Sembera D, El-Naggar AK. Comparative analysis of DNA ploidy and proliferativeindex in fine needle aspirates of non-Hodgkin's lymphomas by image analysis and flow cytometry. Anal Quant CytolHistol 15:151-157, 1993.

111. Ordonez NG, Mackay B, El-Naggar AK, Byers RM. Congenital hemangiopericytoma. An ultrastructural,immunocytochemical, and flow cytometric study. Arch Pathol Lab Med 117:934-937, 1993.

112. McGinnis M, Jacobs G, El-Naggar AK, Redline RW. Congenital peribronchial myofibroblastic tumor (so-called"congenital leiomyosarcoma"). A distinct neonatal lung lesion associated with nonimmune hydrops fetalis. Mod Pathol6:487-492, 1993.

113. Batsakis JG, El-Naggar AK, Hicks MJ. Epithelial choristomas and teratomas of the tongue. Ann Otol Rhinol Laryngol102:567-569, 1993.

114. Cajulis RS, Katz RL, Dekmezian R, El-Naggar AK, Ro JY. Fine needle aspiration biopsy of renal cell carcinoma.Cytologic parameters and their concordance with histology and flow cytometric data. Acta Cytol 37:367-372, 1993.

115. Batsakis JG, Sneige N, El-Naggar AK. Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer.Cancer 71:2151-2153, 1993.

116. Ordonez NG, El-Naggar AK, Ro JY, Silva EG, Mackay B. Intra-abdominal desmoplastic small cell tumor: a lightmicroscopic, immunocytochemical, ultrastructural, and flow cytometric study. Hum Pathol 24:850-865, 1993.

117. Klijanienko J, El-Naggar AK, De Braud F, Micheau C, Janot F, Luboinski B, Gentile A, Russo A, Cvitkovic E. Keratins 6,13 and 19. Differential expression in squamous cell carcinoma of the head and neck. Anal Quant Cytol Histol 15:335-340, 1993.

118. Batsakis JG, El-Naggar AK. Papillary neoplasms (Heffner's tumors) of the endolymphatic sac. Ann Otol Rhinol Laryngol102:648-651, 1993.

119. El-Naggar AK, Ro JY, Ensign LG. Papillary renal cell carcinoma: clinical implication of DNA content analysis. HumPathol 24:316-321, 1993.

120. El-Naggar AK, Batsakis JG, Wang G, Lee MS. PCR-based RFLP screening of the commonly deleted 3p loci in renalcortical neoplasms. Diagn Mol Pathol 2:269-276, 1993.

121. El-Naggar AK, Lee MS, Wang G, Luna MA, Goepfert H, Batsakis JG. Polymerase chain reaction-based restrictionfragment length polymorphism analysis of the short arm of chromosome 3 in primary head and neck squamouscarcinoma. Cancer 72:881-886, 1993.

122. Zavala-Pompa A, Ro JY, El-Naggar AK, Ordonez NG, Amin MB, Pierce PD, Ayala AG. Primary carcinoid tumor oftestis. Immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of theliterature. Cancer 72:1726-1732, 1993.

123. Heaton KM, Rippon MB, El-Naggar AK, Tucker SL, Ross MI, Balch CM. Prognostic implications of DNA index inpatients with stage III cutaneous melanoma. Am J Surg 166:648-652, 1993.

124. Katz RL, Wojcik EM, El-Naggar AK, Ordonez NG, Johnston DA. Proliferation markers in non-Hodgkin's lymphoma. Acomparative study between cytophotometric quantitation of Ki-67 and flow cytometric proliferation index on fine needleaspirates. Anal Quant Cytol Histol 15:179-186, 1993.

125. Ro JY, El-Naggar AK, Amin MB, Sahin AA, Ordonez NG, Ayala AG. Pseudosarcomatous fibromyxoid tumor of theurinary bladder and prostate: immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases.Hum Pathol 24:1203-1120, 1993.

126. Clayman G, Wang SW, Nicolson GL, El-Naggar AK, Mazar A, Henkin J, Blasi F, Goepfert H, Boyd DD. Regulation ofurokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer 54:73-80,1993.

127. El-Naggar AK, Gaber K, Ordonez NG. Renal cell carcinoma with osteoclast-like giant cells. Virchows Arch A PatholAnat Histopathol 422:427-431, 1993.

128. El-Naggar AK, Batsakis JG, Ordonez NG, Luna MA, Goepfert H. Rhabdomyosarcoma of the adult head and neck: a

CV Output


clinicopathological and DNA ploidy study. J Laryngol Otol 107:716-720, 1993.129. Carrillo R, Batsakis JG, Weber R, Luna MA, El-Naggar AK. Salivary neoplasms of the palate: a flow cytometric and

clinicopathological analysis. J Laryngol Otol 107:858-861, 1993.130. Batsakis JG, Hybels RD, El-Naggar AK. Solitary fibrous tumor. Ann Otol Rhinol Laryngol 102:74-76, 1993.131. Stern SJ, Goepfert H, Clayman G, Byers R, Ang KK, El-Naggar AK, Wolf P. Squamous cell carcinoma of the maxillary

sinus. Arch Otolaryngol Head Neck Surg 119:964-969, 1993.132. Scheele, Ro JY, Ordonez NG, El-Naggar AK, Grignon DJ, Sprague RI, Detweiler J, Ayala AG:. Stages B and C

transitional cell carcinomas of the bladder: Prognostic significance of collagen type IV immunostaining patterns andtheir comparison with other clinicopathologic prognosticators. . J Urologic Pathology 2:121-133, 1993.

133. Batsakis JG, El-Naggar AK. Wegener's granulomatosis and antineutrophil cytoplasmic autoantibodies. Ann Otol RhinolLaryngol 102:906-908, 1993.

134. Sanchez Y, El-Naggar AK, Pathak S, Killary AM. A tumor suppressor locus within 3p14-p12 mediates rapid cell deathof renal cell carcinoma in vivo. Proc Natl Acad Sci U S A 91:3383-3387, 1994.

135. El-Naggar AK, Barlogie B, McCabe K, Teague K, Ensign LG, Pollock RE. Acridine orange DNA/RNA content analysis ofsoft-tissue tumors: Correlation with clinicopathologic factors and biological behavior. CMS 1:237-247, 1994.

136. Press, Pike MC, Hung G, Zhou JY, George J, Dietz-Bank J, James W, Slamon DJ, Batsakis JG, El-Naggar AK:.Amplification and overexpression of HER-2/neu in carcinoma of the salivary gland: Correlation with poor prognosis. .Cancer Research 54:5675-5682, 1994.

137. Chandler D, El-Naggar AK, Brisbay S, Redline RW, McDonnell TJ. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renalcarcinogenesis. Hum Pathol 25:789-796, 1994.

138. Ordonez, El-Naggar AK, Ro JY, Silva EG, Mackay B:. Argyrophil cell differentiation of Wilms’ tumor (To the Editor). .Human Pathology 25:109-110, 1994.

139. Ro JY, Guerrieri C, El-Naggar AK, Ordonez NG, Sorge JG, Ayala AG. Carcinomas metastatic to follicular adenomas ofthe thyroid gland. Report of two cases. Arch Pathol Lab Med 118:551-556, 1994.

140. Steck K, El-Naggar AK. Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) insolid neoplasms. Cytometry 17:258-265, 1994.

141. Teague K, El-Naggar AK. Comparative flow cytometric analysis of proliferating cell nuclear antigen (PCNA) antibodiesin human solid neoplasms. Cytometry 15:21-27, 1994.

142. Marin MC, Hsu B, Meyn RE, Donehower LA, El-Naggar AK, McDonnell TJ. Evidence that p53 and bcl-2 are regulatorsof a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107-3112, 1994.

143. Frankenthaler RA, El-Naggar AK, Ordonez NG, Miller TS, Batsakis JG. High correlation with survival of proliferating cellnuclear antigen expression in mucoepidermoid carcinoma of the parotid gland. Otolaryngol Head Neck Surg 111:460-466, 1994.

144. Clayman GL, Stewart MG, Weber RS, El-Naggar AK, Grimm EA. Human papillomavirus in laryngeal andhypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg 120:743-748, 1994.

145. Batsakis JG, El-Naggar AK, Luna MA. Hyalinizing clear cell carcinoma of salivary origin. Ann Otol Rhinol Laryngol103:746-748, 1994.

146. El-Naggar AK, van Dekken HD, Ensign LG, Pathak S. Interphase cytogenetics in paraffin-embedded sections fromrenal cortical neoplasms. Correlation with cytogenetic and flow cytometric DNA ploidy analyses. Cancer GenetCytogenet 73:134-141, 1994.

147. Carrillo R, Sneige N, El-Naggar AK. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.Acta Cytol 38:367-372, 1994.

148. Manning JT, Jr, Pugh WC, El-Naggar AK, Ordonez NG. Mediastinal lymphoblastic lymphoma with non-lymphoblastichistologic features. Mod Pathol 7:59-63, 1994.

149. Pollack A, Zagars GK, El-Naggar AK, Gauwitz MD, Terry NH. Near-diploidy: a new prognostic factor for clinicallylocalized prostate cancer treated with external beam radiation therapy. Cancer 73:1895-1903, 1994.

150. Buzaid A, Legha SS, Balch CM, Ross M, Ring S, Plager C, Papadopoulos NE, El-Naggar AK, Benjamin RS. Pilot studyof preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence ofmelanoma. Cancer 74:2476-2482, 1994.

151. Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogeneamplification in primary head and neck squamous cell carcinoma. Cancer 74:152-158, 1994.

152. Hicks MJ, El-Naggar AK, Byers RM, Flaitz CM, Luna MA, Batsakis JG. Prognostic factors in mucoepidermoidcarcinomas of major salivary glands: a clinicopathologic and flow cytometric study. Eur J Cancer B Oral Oncol30B:329-334, 1994.

153. Batsakis JG, El-Naggar AK. Pseudosarcomatous proliferative lesions of soft tissues. Ann Otol Rhinol Laryngol 103:578-582, 1994.

154. Yildiz I, Jaffe N, Aksoy F, El-Naggar AK. Regional DNA content heterogeneity in Wilms' tumor: incidence and potentialclinical relevance. Anticancer Res 14:1365-1369, 1994.

155. Pollack A, Zagars GK, E-Naggar AK, Terry NH. Relationship of tumor DNA-ploidy to serum prostate-specific antigen

CV Output


doubling time after radiotherapy for prostate cancer. Urology 44:711-718, 1994.156. Heaton KM, El-Naggar AK, Ensign LG, Ross MI, Balch CM. Surgical management and prognostic factors in patients

with subungual melanoma. Ann Surg 219:197-204, 1994.157. Gauwitz MD, Pollack A, El-Naggar AK, Terry NH, von Eschenbach AC, Zagars GK. The prognostic significance of DNA

ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 28:821-828,1994.

158. El-Naggar AK, Lovell M, Killary A, Batsakis JG. Trisomy 5 as the sole chromosomal abnormality in a primarymucoepidermoid carcinoma of the minor salivary gland. Cancer Genet Cytogenet 76:96-99, 1994.

159. Zavala-Pompa A, Ro JY, El-Naggar AK, Amin MB, Ordonez NG, Sella A, Ayala AG. Tubular seminoma. Animmunohistochemical and DNA flow-cytometric study of four cases. Am J Clin Pathol 102:397-401, 1994.

160. El-Naggar AK, Pflatz M, Ordonez NG, Batsakis JG. Tumors of the middle ear and endolymphatic sac. Pathol Annu 29 (Pt 2):199-231, 1994.

161. Batsakis JG, El-Naggar AK, Weber RS. Two perplexing skin tumors: microcystic adnexal carcinoma andkeratoacanthoma. Ann Otol Rhinol Laryngol 103:829-832, 1994.

162. Mackay B, El-Naggar AK, Ordonez NG. Ultrastructure of adrenal cortical carcinoma. Ultrastruct Pathol 18:181-190,1994.

163. Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL. Apoptosis induction mediated bywild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 55:3117-3122,1995.

164. Cho KJ, Ell-Naggar AK, Mahanupab P, Luna MA, Batsakis JG. Carcinoma ex-pleomorphic adenoma of the nasal cavity:a report of two cases. J Laryngol Otol 109:677-679, 1995.

165. Giannoni C, El-Naggar AK, Ordonez NG, Tu ZN, Austin J, Luna MA, Batsakis JG. c-erbB-2/neu oncogene and Ki-67analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg 112:391-398, 1995.

166. el-Kattan I, Redline RW, El-Naggar AK, Grimes MC, Abdul-Karim FW. Cytologic features of intraabdominaldesmoplastic small round cell tumor. A case report. Acta Cytol 39:514-520, 1995.

167. Wojcik EM, Katz RL, Fanning TV, El-Naggar AK, Ordonez NG, Johnston D. Diagnosis of mantle cell lymphoma ontissue acquired by fine needle aspiration in conjunction with immunocytochemistry and cytokinetic studies. Possibilitiesand limitations. Acta Cytol 39:909-915, 1995.

168. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potentialdiagnostic implications. Am J Pathol 147:815-822, 1995.

169. El-Naggar AK, Hurr K, Tu ZN, Teague K, Raymond KA, Ayala AG, Murray J. DNA and RNA content analysis by flowcytometry in the pathobiologic assessment of bone tumors. Cytometry 19:256-262, 1995.

170. Rajagopal S, Huang S, Moskal TL, Lee BN, El-Naggar AK, Chakrabarty S. Epidermal growth factor expression inhuman colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferationof human colon cancer cells. Int J Cancer 62:661-667, 1995.

171. Cho KJ, El-Naggar AK, Ordonez NG, Luna MA, Austin J, Batsakis JG. Epithelial-myoepithelial carcinoma of salivaryglands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene.Am J Clin Pathol 103:432-437, 1995.

172. Hsu B, Marin MC, El-Naggar AK, Stephens LC, Brisbay S, McDonnell TJ. Evidence that c-myc mediated apoptosisdoes not require wild-type p53 during lymphomagenesis. Oncogene 11:175-179, 1995.

173. Janot F, El-Naggar AK, Morrison RS, Liu TJ, Taylor DL, Clayman GL. Expression of basic fibroblast growth factor insquamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. Int J Cancer64:117-123, 1995.

174. Steck KD, McDonnell TJ, El-Naggar AK. Flow cytometric analysis of apoptosis and bcl-2 in human solid neoplasms.Cytometry 20:154-161, 1995.

175. Lai, Batsakis JG, Ordonez NG, Luna MA, Goepfert H, El-Naggar AK:. Genotypic and phenotypic alterations of p53 inhead and neck squamous cell carcinoma. . Oncology Report 2:1115-1120, 1995.

176. Roush GR, El-Naggar AK, Abdul-Karim FW. Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNAanalysis. Gynecol Oncol 56:430-434, 1995.

177. El-Naggar AK, Steck K, Batsakis JG. Heterogeneity of the proliferative fraction and cyclin D1/CCND1 gene amplificationin head and neck squamous cell carcinoma. Cytometry 21:47-51, 1995.

178. Hicks MJ, El-Naggar AK, Flaitz CM, Luna MA, Batsakis JG. Histocytologic grading of mucoepidermoid carcinoma ofmajor salivary glands in prognosis and survival: a clinicopathologic and flow cytometric investigation. Head Neck17:89-95, 1995.

179. A Aydin, El-Naggar AK, Robertson LE, Keating MJ, Huh YO. IL-2 receptor expression and KI-67 flow cytometricanalysis in B-chronic lymphocytic leukemia. . Int J Oncol 7:1433-1436, 1995.

180. AA Sahin, Sneige N, Ordonez NG, Singletary SE, Ro JY, El-Naggar AK, Ayala AG. Immunohistochemical assessmentof cathepsin D in stages I and II node-negative breast cancer. . Appl Immunohistochemistry 2:15-21, 1995.

181. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ. In vivo molecular therapy with p53adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1-6, 1995.

CV Output


182. El-Naggar AK, Hurr K, Tu ZN, Tucker SL, Swanson D, Hsu PH. Interphase cytogenetics of renal cortical neoplasms.Correlation with DNA ploidy by flow cytometry. Am J Clin Pathol 104:141-149, 1995.

183. BL Kemp, Silva EG, El-Naggar AK. Juvenile granulosa cell tumor of the ovary: Interphase cytogenetics forchromosomes 12 and X and flow cytometric DNA ploidy study. . International Journal of Oncology 7:661-665, 1995.

184. M Cervantes, Zhou H, Sahin A, Dhingra K, Valero V, Ordonez N, El-Naggar AK, Hess K, Glassman A, Sen S:. p53alterations show significant correlation with gene amplification and high S-phase index in breast carcinoma. .International Journal of Oncology 6:955-962, 1995.

185. Kanjilal S, Strom SS, Clayman GL, Weber RS, El-Naggar AK, Kapur V, Cummings KK, Hill LA, Spitz MR, Kripke ML,Ananthaswang HN. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for fieldcancerization. Cancer Res 55:3604-3609, 1995.

186. El-Naggar AK, Troncoso P, Ordonez NG. Primary renal carcinoid tumor with molecular abnormality characteristic ofconventional renal cell neoplasms. Diagn Mol Pathol 4:48-53, 1995.

187. Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, El-Naggar AK. Rhabdomyosarcoma of the nose andparanasal sinuses in adults and children. Otolaryngol Head Neck Surg 112:252-257, 1995.

188. El-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H, Huff V. Sequential loss of heterozygosity at microsatellitemotifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55:2656-2659, 1995.

189. El-Naggar AK, Lai S, Luna MA, Zhou XD, Weber RS, Goepfert H, Batsakis JG. Sequential p53 mutation analysis ofpre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 64:196-201, 1995.

190. Lee JE, Berger DH, El-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, Burgess MA, Evans DB. Surgicalmanagement, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118:1090-1098, 1995.

191. Kemp BL, Batsakis JG, El-Naggar AK, Kotliar SN, Luna MA. Terminal duct adenocarcinomas of the parotid gland. JLaryngol Otol 109:466-468, 1995.

192. Klijanienko J, El-Naggar AK, de Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Janot F, Luboinski B,Cvitkovic E. Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114head and neck squamous cell carcinomas. Cancer 75:1649-1656, 1995.

193. El-Naggar AK, Lovell M, Killary AM, Clayman GL, Batsakis JG. A mucoepidermoid carcinoma of minor salivary glandwith t(11;19)(q21;p13.1) as the only karyotypic abnormality. Cancer Genet Cytogenet 87:29-33, 1996.

194. MI Colome, Ro JY, Ayala AG, El-Naggar AK, Siddiqui RT, Ordonez NG:. Adenoid cystic carcinoma of the breastmetastatic to the kidney. . Int J Urol 4:69-78, 1996.

195. El-Naggar AK, Hurr K, Huff V, Luna MA, Goepfert H, Batsakis JG. Allelic loss and replication errors at microsatellite locion chromosome 11p in head and neck squamous carcinoma: association with aggressive biological features. ClinCancer Res 2:903-907, 1996.

196. Torres C, Ro JY, El-Naggar AK, Sim SJ, Weber RS, Ayala AG. Allergic fungal sinusitis: a clinicopathologic study of 16cases. Hum Pathol 27:793-799, 1996.

197. El-Naggar AK, Kemp BL, Sneige N, Hurr KG, Steck K, Tu ZN, Fritsche HA, Singletary SE, Balch CM. Bivariate RNAand DNA content analysis in breast carcinoma: biological significance of RNA content. Clin Cancer Res 2:419-426,1996.

198. Ling YH, El-Naggar AK, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruptionof p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49:832-841, 1996.

199. Suarez PA, Batsakis JG, El-Naggar AK. Don't confuse dental soft tissues with odontogenic tumors. Ann Otol RhinolLaryngol 105:490-494, 1996.

200. Batsakis JG, Mackay B, El-Naggar AK. Ewing's sarcoma and peripheral primitive neuroectodermal tumor: an interimreport. Ann Otol Rhinol Laryngol 105:838-843, 1996.

201. Gillenwater A, Xu XC, El-Naggar AK, Clayman GL, Lotan R. Expression of galectins in head and neck squamous cellcarcinoma. Head Neck 18:422-432, 1996.

202. Sastry KJ, Marin MC, Nehete PN, McConnell K, El-Naggar AK, McDonnell TJ. Expression of human immunodeficiencyvirus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene 13:487-493, 1996.

203. Ligato S, El-Naggar AK, Cleary KR, Manning J. Extramedullary plasmacytoma mimicking primary colonic carcinoma in apatient with Crohn's disease. Case report and literature review. Arch Pathol Lab Med 120:279-282, 1996.

204. Steck K, McDonnell T, Sneige N, El-Naggar AK. Flow cytometric analysis of apoptosis and bcl-2 in primary breastcarcinomas: clinical and biological implications. Cytometry 24:116-122, 1996.

205. El-Naggar AK, Dinh M, Tucker S, Luna MA, Goepfert H, Hsu P, Batsakis JG. Genotypic analysis of primary head andneck squamous carcinoma by combined fluorescence in situ hybridization and DNA flow cytometry. Am J Clin Pathol105:102-8, 1996.

206. El-Naggar AK, Lovell M, Killary AM, Batsakis JG. Genotypic characterization of a primary mucoepidermoid carcinoma ofthe parotid gland by cytogenetic, fluorescence in situ hybridization, and DNA ploidy analysis. Cancer Genet Cytogenet89:38-43, 1996.

207. Sneige N, Sahin A, Dinh M, El-Naggar AK. Interphase cytogenetics in mammographically detected breast lesions. HumPathol 27:330-335, 1996.

CV Output


208. Linden MD, El-Naggar AK, Nathanson SD, Jacobson G, Zarbo RJ. Lack of correlation between flow cytometric andimmunohistologic proliferation measurements of tumors. Mod Pathol 6:682-689, 1996.

209. TM Voytek, Ro JY, El-Naggar AK, Ordonez NG, Tornos C, Welch GR, Ayala AG. Metastatic ovarian granulosa celltumor to urinary bladder mimicking primary transitional cell carcinoma. . Int J Urol 4:57-67, 1996.

210. Hurr K, Kemp B, Silver SA, El-Naggar AK. Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance. Am J Pathol 149:613-620, 1996.

211. El-Naggar AK, Hurr K, Huff V, Clayman GL, Luna MA, Batsakis JG. Microsatellite instability in preinvasive and invasivehead and neck squamous carcinoma. Am J Pathol 148:2067-2072, 1996.

212. El-Naggar AK, Luna MA, Goepfert H, Batsakis JG. Molecular and immunohistochemical analysis of the p53 gene inhead and neck squamous tumorigenesis. . Head and Neck Cancer - Advances in Basic Research:297-306, 1996.

213. El-Naggar AK, Goepfert H, Batsakis JG:. Molecular genetic analysis of head and neck squamous tumorigenesis bymicrosatellite markers. . Head and Neck Cancer - Advances in Basic Research:169-177, 1996.

214. JR Austin, Cebrun H, Kershisnik MM, El-Naggar AK, Garden AS, DeMonte F, Ginsberg LE, Lippman SM, Goepfert H:.Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: Treatment results at the M.D.Anderson Cancer Center. . Skull Base Surgery 6:1-8, 1996.

215. Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I, Tucker SL, Luna MA, Batsakis JG. Prognostic significanceof biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. HumPathol 27:561-566, 1996.

216. Janot F, Klijanienko J, Russo A, Mamet JP, de Braud F, El-Naggar AK, Pignon JP, Luboinski B, Cvitkovic E. Prognosticvalue of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br JCancer 73:531-538, 1996.

217. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE,Evans DB. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superiormesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 223:154-162, 1996.

218. Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutatedtumor cells. Oncogene 12:2035-2039, 1996.

219. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK. Telomerase activity in head andneck squamous cell carcinoma and adjacent tissues. Cancer Res 56:5600-5604, 1996.

220. M Sarkiss, Hsu B, El-Naggar AK, McDonnell TJ. The clinical relevance of assessment of apoptotic cell death.Advances in Anatomic Pathology 4:205-211, 1996.

221. Batsakis JG, El-Naggar AK, Luna MA. Thyroid gland ectopias. Ann Otol Rhinol Laryngol 105:996-1000, 1996.222. Wang RY, Troncoso P, Palmer JL, El-Naggar AK, Liang JC. Trisomy 7 by dual-color fluorescence in situ hybridization:

a potential biological marker for prostate cancer progression. Clin Cancer Res 2:1553-1558, 1996.223. G Clayman, El-Naggar AK Merritt J, Bruso P, Roth JA, Lippman S, Hong WK, Goepfert H. Adenovirus-Mediated p53

Gene Transfer in a Phase I Trial of Patients with Advanced Recurrent Head and Neck Squamous Cell Carcinoma. .Proc Annu Meet Am Soc Clin Oncol 16:A1363, 1997.

224. Klijanienko J, El-Naggar AK, Servois V, Rodriguez J, Validire P, Vielh P. Clinically aggressive metastasizingpleomorphic adenoma: report of two cases. Head Neck 19:629-633, 1997.

225. Pisters LL, El-Naggar AK, Luo W, Malpica A, Lin SH. C-met proto-oncogene expression in benign and malignanthuman renal tissues. J Urol 158:724-872, 1997.

226. Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head andneck squamous cell carcinoma. Oncogene 14:369-373, 1997.

227. Cagle PT, El-Naggar AK, Xu HJ, Hu SX, Benedict WF. Differential retinoblastoma protein expression in neuroendocrinetumors of the lung. Potential diagnostic implications. Am J Pathol 150:393-400, 1997.

228. S Eissa, Wahed MA, Ismail A, Amer K, Khalifa, El-Naggar AK. DNA ploidy in Hepatic Cirrhosis, Dysplasia andCarcinoma: Evidence of Clonal Progression. . Oncology Reports 4:441-445, 1997.

229. RE Pollock, Lang A, El-Naggar AK, Radinsky R, Hung MC. Enchanced MDM2 Oncoprotein Expression in Soft TissueSarcoma: Several Possible Regulatory Mechanisms. . Sarcoma 1:23-29, 1997.

230. El-Naggar AK, Hurr K, Kagan J, Gillenwater A, Callender D, Luna MA, Batsakis JG. Genotypic alterations in benignand malignant salivary gland tumors: histogenetic and clinical implications. Am J Surg Pathol 21:691-697, 1997.

231. Overholt SM, Liu TJ, Taylor DL, Wang M, El-Naggar AK, Shillitoe E, Adler-Storthz K, John LS, Zhang WW, Roth JA,Clayman GL. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker forgene therapy trials. Clin Cancer Res 3:185-191, 1997.

232. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar AK,Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescencein situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997.

233. El-Naggar AK, Hurr K, Luna MA, Goepfert H, Hong WK, Batsakis JG. Intratumoral genetic heterogeneity in primaryhead and neck squamous carcinoma using microsatellite markers. Diagn Mol Pathol 6:305-308, 1997.

234. Klijanienko, Servois V, Jammet P, Validire P, Pouillart P, Vielh P, El-Naggar AK, Dulmet E:. Letter to the Editor:Pleomorphic Adenoma. . AM J Surg Pathol. 21:13-22, 1997.

CV Output


235. Lai S, Benedict WF, Silver SA, El-Naggar AK. Loss of retinoblastoma gene function and heterozygosity at the RB locusin renal cortical neoplasms. Hum Pathol 28:693-697, 1997.

236. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG. Methylation, a major mechanism ofp16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 151:1767-1774, 1997.

237. Gillenwater A, Hurr K, Wolf P, Batsakis JG, Goepfert H, El-Naggar AK. Microsatellite alterations at chromosome 8q lociin pleomorphic adenoma. Otolaryngol Head Neck Surg 117:448-452, 1997.

238. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-NaggarAK, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK,Fujii G, Berson A, Steck PA, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. CancerRes 57:5221-5225, 1997.

239. Gershenson DM, Baker VV, Price JE, Hung MC, El-Naggar AK, Tortolero-Luna G, Silva EG. Molecular profile ofadvanced-stage transitional cell carcinoma of the ovary. Am J Obstet Gynecol 177:120-125, 1997.

240. Meterissian SH, Skibber JM, Giacco GG, El-Naggar AK, Hess KR, Rich TA. Pelvic exenteration for locally advancedrectal carcinoma: factors predicting improved survival. Surgery 121:479-87, 1997.

241. Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ. Postoperative radiotherapy for malignanttumors of the parotid gland. Int J Radiat Oncol Biol Phys 37:79-85, 1997.

242. Silva EG, Tornos C, Fritsche HA, Jr, El-Naggar AK, Gray K, Ordonez NG, Luna M, Gershenson D. The induction ofbenign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. ModPathol 10:879-883, 1997.

243. Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ,Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients withadvanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998.

244. Byers RM, El-Naggar AK, Lee Y-Y, Rao B, Fornage B, Terry NHA, Sample D, Hankins P, Smith TL, Wolf PJ. Can wedetect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue?Head and Neck 20:138-144, 1998.

245. El-Naggar AK, Lovell M, Callender DL, Ordonez NG, Killary AM. Concurrent cytogenetic, interphase fluorescence in situhybridization and DNA flow cytometric analyses of a carcinoma ex-pleomorphic adenoma of parotid gland. CancerGenet Cytogenet 107:132-136, 1998.

246. Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarguen H, Lee JS, Ro JY, El-Naggar AK, Hong WK, Hittelman WN.Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association withsubsequent gene amplification. Oncogene 17:2313-2322, 1998.

247. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, HongWK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25:33-37, 1998.

248. El-Naggar AK, Abdul-Karim FW, Hurr K, Callender D, Luna MA, Batsakis JG. Genetic alterations in acinic cellcarcinoma of the parotid gland determined by microsatellite analysis. Cancer Genet Cytogenet 102:19-24, 1998.

249. Coombes MM, Mao L, Steck KD, Luna MA, El-Naggar AK. Genotypic analysis of flow-sorted and microdissected headand neck squamous lesions by whole-genome amplification. Diagn Mol Pathol 7:197-201, 1998.

250. Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar AK, Yu D. Infrequent mutation of the p16/MTS1gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res 4:1065-1070, 1998.

251. El-Naggar AK, Coombes MM, Batsakis JG, Hong WK, Goepfert H, Kagan J. Localization of chromosome 8p regionsinvolved in early tumorigenesis of oral and laryngeal squamous carcinoma. Oncogene 16:2983-2987, 1998.

252. Klijanienko J, El-Naggar AK, Servois V, Rodriguez J, Validire P, Vielh P. Mucoepidermoid carcinoma ex pleomorphicadenoma: nonspecific preoperative cytologic findings in six cases. Cancer 84:231-234, 1998.

253. El-Naggar AK, Lovell M, Ordonez NG, Killary AM. Multiple unrelated translocations in a metastatic epimyoepithelialcarcinoma of the parotid gland. Cancer Genet Cytogenet 100:155-158, 1998.

254. Gillenwater A, Jacob R, Ganeshappa R, Kemp B, El-Naggar AK, Palmer JL, Clayman G, Mitchell MF, Richards-KortumR. Noninvasive diagnosis of oral neoplasia based on fluorescence spectroscopy and native tissue autofluorescence.Arch Otolaryngol Head Neck Surg 124:1251-1258, 1998.

255. Dubey P, Ha CS, Ang KK, El-Naggar AK, Knapp C, Byers RM, Morrison WH. Nonnasopharyngeal lymphoepithelioma ofthe head and neck. Cancer 82:1556-1562, 1998.

256. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS,Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesionsafter chemopreventive therapy. J Natl Cancer Inst 90:1545-1551, 1998.

257. Papadimitrakopoulou VA, Oh Y, El-Naggar AK, Izzo J, Clayman G, Mao L. Presence of multiple incontiguous deletedregions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 4:539-544, 1998.

258. Roberts HL, Komaki R, Allen P, El-Naggar AK. Prognostic significance of DNA content in stage I adenocarcinoma ofthe lung. Int J Radiat Oncol Biol Phys 41:573-578, 1998.

CV Output


259. Ballo MT, Garden AS, El-Naggar AK, Gillenwater AM, Morrison WH, Goepfert H, Ang KK. Radiation therapy for earlystage (T1-T2) sarcomatoid carcinoma of true vocal cords: outcomes and patterns of failure. Laryngoscope 108:760-763, 1998.

260. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis JG, El-Naggar AK.The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma.Cancer 82:2159-2165, 1998.

261. Woods KV, El-Naggar AK, Clayman GL, Grimm EA. Variable expression of cytokines in human head and necksquamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58:3132-3141, 1998.

262. Fordice J, Kershaw C, El-Naggar AK, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors ofmorbidity and mortality. Arch Otolaryngol Head Neck Surg 125:149-152, 1999.

263. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F,Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-SolerR, Pisters KM, Putnam JB, Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D,Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst91:763-771, 1999.

264. Delehedde M, Cho SH, Sarkiss M, Brisbay S, Davies M, El-Naggar AK, McDonnell TJ. Altered expression of bcl-2family member proteins in nonmelanoma skin cancer. Cancer 85:1514-1522, 1999.

265. Liu TJ, Wang M, Breau RL, Henderson Y, El-Naggar AK, Steck KD, Sicard MW, Clayman GL. Apoptosis induction byE2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinomacell lines. Cancer Gene Ther 6:163-171, 1999.

266. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS,Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch OtolaryngolHead Neck Surg 125:1083-1089, 1999.

267. Amin MB, de Peralta-Venturina MN, Ro JY, El-Naggar AK, Mackay B, Ordonez N, Mani A, Ayala A. Clear cell sarcomaof kidney in an adolescent and in young adults: a report of four cases with ultrastructural, immunohistochemical, andDNA flow cytometric analysis. Am J Surg Pathol 23:1455-1463, 1999.

268. Klijanienko J, El-Naggar AK, Vielh P. Comparative cytologic and histologic study of fifteen salivary basal-cell tumors:differential diagnostic considerations. Diagn Cytopathol 21:30-34, 1999.

269. El-Naggar AK, Lovell M, Callender DL, Ordonez NG, Killary AM. Cytogenetic analysis of a primary salivary glandmyoepithelioma. Cancer Genet Cytogenet 113:49-53, 1999.

270. Klijanienko J, Couturier J, Galut M, El-Naggar AK, Maciorowski Z, Padoy E, Mosseri V, Vielh P. Detection andquantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breastcancer fine-needle samples. Cancer 87:312-318, 1999.

271. Lai S, El-Naggar AK. Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamouscarcinomas. Lab Invest 79:255-260, 1999.

272. El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers J, Luna MA, Benedict WF. Expression of p16, Rb, andcyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol30:1013-1018, 1999.

273. Brunnemann RB, Ro JY, Ordonez NG, Mooney J, El-Naggar AK, Ayala AG. Extrapleural solitary fibrous tumor: aclinicopathologic study of 24 cases. Mod Pathol 12:1034-1042, 1999.

274. Klijanienko J, El-Naggar AK, Vielh P. Fine-needle sampling findings in 26 carcinoma ex pleomorphic adenomas:diagnostic pitfalls and clinical considerations. Diagn Cytopathol 21:163-166, 1999.

275. Steck K, Hunt K, Tucker S, Singletary S, El-Naggar AK. Flow cytometric analysis of Ki-67 in invasive ductal carcinomaof the breast: correlation with tumor and patient characteristics. Oncol Rep 6:835-838, 1999.

276. El-Naggar AK, Lai S, Tucker SA, Clayman GL, Goepfert H, Hong WK, Huff V. Frequent loss of imprinting at the IGF2and H19 genes in head and neck squamous carcinoma. Oncogene 18:7063-7069, 1999.

277. Jin YT, Myers J, Tsai ST, Goepfert H, Batsakis JG, El-Naggar AK. Genetic alterations in oral squamous cell carcinomaof young adults. Oral Oncol 35:251-256, 1999.

278. Klijanienko J, El-Naggar AK, Servois V, Rodriguez J, Desjardins L, Schlienger P, Validire P, Vielh P. Histologicallysimilar, synchronous or metachronous, lacrimal salivary-type and parotid gland tumors: A series of 11 cases. HeadNeck 21:512-516, 1999.

279. El-Naggar AK, Lovell M, Callender DL, Killary AM. Limited nonrandom chromosomal aberrations in a recurrent adenoidcystic carcinoma of the parotid gland. Cancer Genet Cytogenet 109:66-69, 1999.

280. Qiu H, Zhang W, El-Naggar AK, Lippman SM, Lin P, Lotan R, Xu XC. Loss of retinoic acid receptor-beta expression isan early event during esophageal carcinogenesis. Am J Pathol 155:1519-1523, 1999.

281. Evans SC, Foster CJ, El-Naggar AK, Lozano G. Mapping and mutational analysis of the human TAF2G gene encodinga p53 cofactor. Genomics 57:182-183, 1999.

282. Batsakis JG, El-Naggar AK. Myoepithelium in salivary and mammary neoplasms is host-friendly. Adv Anat Pathol6:218-226, 1999.

283. El-Naggar AK, Dinh M, Tucker SL, Swanson D, Steck K, Vielh P. Numerical chromosomal changes in DNA hypodiploid

CV Output


solid tumors: restricted loss and gain of certain chromosomes. Cytometry 37:107-112, 1999.284. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El-Naggar AK,

Press MF. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol18:29-41, 1999.

285. Batsakis JG, Suarez P, El-Naggar AK. Proliferative verrucous leukoplakia and its related lesions. Oral Oncol 35:354-359, 1999.

286. Lovell M, Lott ST, Wong P, El-Naggar AK, Tucker S, Killary AM. The genetic locus NRC-1 within chromosome 3p12mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, andVHL mutation. Cancer Res 59:2182-2189, 1999.

287. Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE. Adenovirus-mediated p53 gene therapy inhibitshuman sarcoma tumorigenicity. Cancer Gene Ther 7:422-429, 2000.

288. Audebert M, Chevillard S, Levalois C, Gyapay G, Vieillefond A, Klijanienko J, Vielh P, El Naggar AK, Oudard S, BoiteuxS, Radicella JP. Alterations of the DNA repair gene OGG1 in human clear cell carcinomas of the kidney. Cancer Res60:4740-4744, 2000.

289. Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar AK, Shin HJ, Lee JJ, Lee JS, Gillenwater A, MyersJ, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of thehead and neck and p53 gene expression. J Natl Cancer Inst 92:69-73, 2000.

290. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS,Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R,Pisters KM, Putnam JB, Jr, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses toadenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7:530-536, 2000.

291. Dano L, Guilly MN, Muleris M, Morlier JP, Altmeyer S, Vielh P, El-Naggar AK, Monchaux G, Dutrillaux B, Chevillard S.CGH analysis of radon-induced rat lung tumors indicates similarities with human lung cancers. Genes ChromosomesCancer 29:1-8, 2000.

292. Maciorowski Z, Klijanienko J, Padoy E, Mosseri V, Dieras V, El-Naggar AK, Chevillard S, Vielh P. Differentialexpression of Bax and Bcl-2 in the assessment of cellular dynamics in fine-needle samples of primary breastcarcinomas. Cytometry 42:264-269, 2000.

293. Xu XC, Sola Gallego JJ, Lotan R, El-Naggar AK. Differential expression of galectin-1 and galectin-3 in benign andmalignant salivary gland neoplasms. Int J Oncol 17:271-276, 2000.

294. Clifford JL, Menter DG, Yang X, Walch E, Zou C, Clayman GL, Schaefer TS, El-Naggar AK, Lotan R, Lippman SM.Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. CancerEpidemiol Biomarkers Prev 9:993-997, 2000.

295. Tae K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM. Expression of vascular endothelialgrowth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 6:2821-2828, 2000.

296. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. High metastatic potentialin mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97:4174-4179, 2000.

297. Lau WY-K, HU M C-T, Li L, Johnston DA, Sheng S-J, El-Naggar AK, Hung M-C:. High tumoral maspin expression isassociated with improved survival of patients with oral squamous cell carcinoma. . Oncogene 19:2398-2403, 2000.

298. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL. In vivoexpression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156:1937-1950,2000.

299. Barnett CC, Jr, Varma DG, El-Naggar AK, Dackiw AP, Porter GA, Pearson AS, Kudelka AP, Gagel RF, Evans DB, LeeJE. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 128:973-982, 2000.

300. Lai S, Goepfert H, Gillenwater AM, Luna MA, El-Naggar AK. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma. Clin Cancer Res 6:3172-3176,2000.

301. El-Naggar AK, Callender D, Coombes MM, Hurr K, Luna MA, Batsakis JG. Molecular genetic alterations in carcinomaex-pleomorphic adenoma: a putative progression model? Genes Chromosomes Cancer 27:162-168, 2000.

302. Williamson JD, Simmons BH, El-Naggar AK, Medeiros LJ. Mucoepidermoid carcinoma involving Warthin tumor. A reportof five cases and review of the literature. Am J Clin Pathol 114:564-570, 2000.

303. Suarez PA, Adler-Storthz K, Luna MA, El-Naggar AK, Abdul-Karim FW, Batsakis JG. Papillary squamous cellcarcinomas of the upper aerodigestive tract: a clinicopathologic and molecular study. Head Neck 22:360-368, 2000.

304. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM,Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: tenyears of translational research. Clin Cancer Res 6:1702-1710, 2000.

305. Sorensen DM, Gokden M, El-Naggar AK, Byers RM. Quiz case 1. Periosteal osteosarcoma (PO) of the mandible. ArchOtolaryngol Head Neck Surg 126:550-552, 2000.

306. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 productincreases p53 activity by inhibiting HDM2. Oncogene 20:4041-4049, 2001.

CV Output


307. Kim J, Shin DM, El-Naggar AK, Lee JS, Corrales C, Lippman SM, Hong WK, Hittelman WN. Chromosome polysomyand histological characteristics in oral premalignant lesions. Cancer Epidemiol Biomarkers Prev 10:319-325, 2001.

308. Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression insquamous cell carcinoma of the tongue. Clin Cancer Res 7:2458-2462, 2001.

309. Maciorowski Z, Klijanienko J, Padoy E, Mosseri V, Fourquet A, Chevillard S, El-Naggar AK, Vielh P. Comparativeimage and flow cytometric TUNEL analysis of fine needle samples of breast carcinoma. Cytometry 46:150-156, 2001.

310. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar AK, Minguillon C, Schonborn I,Reich O, Kreienberg R, Lichtenegger W, Press MF. Correlation of p53 mutations with resistance to platinum-basedchemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984-2997, 2001.

311. Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar AK, den Hollander P, Liu D,Hittelman WN, Hong WK. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestivetract: role in response to chemoprevention and cancer development. Clin Cancer Res 7:3127-3134, 2001.

312. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes thatregulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol158:735-743, 2001.

313. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M.Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.Br J Haematol 112:749-759, 2001.

314. Klijanienko J, Lagace R, Servois V, Lussier C, El-Naggar AK, Vielh P. Fine-needle sampling of primary neuroendocrinecarcinomas of salivary glands: cytohistological correlations and clinical analysis. Diagn Cytopathol 24:163-166, 2001.

315. El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, Clayman GL, Lippman S, Goepfert H. Geneticheterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis andscreening. J Mol Diagn 3:164-170, 2001.

316. Lee JI, Soria JC, Hassan K, Liu D, Tang X, El-Naggar AK, Hong WK, Mao L. Loss of Fhit expression is a predictor ofpoor outcome in tongue cancer. Cancer Res 61:837-841, 2001.

317. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, Hong WK, Mao L. Loss of PTEN expression as aprognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127:1441-1445, 2001.

318. Spring PM, Myers JN, El-Naggar AK, Langstein HN. Malignant melanoma arising within a burn scar case report andreview of the literature. Ann Otol Rhinol Laryngol 110:369-376, 2001.

319. Hoang MP, Callender DL, Sola Gallego JJ, Huang Z, Sneige N, Luna MA, Batsakis JG, El-Naggar AK. Molecular andbiomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int J Oncol 19:865-871,2001.

320. El-Naggar AK, Lai S, Clayman GL, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. p73 gene alterations andexpression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 22:729-735, 2001.

321. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X,Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study ofthe antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.Cancer 92:2364-2373, 2001.

322. Jiang W, Ananthaswamy HN, Muller HK, Ouhtit A, Bolshakov S, Ullrich SE, El-Naggar AK, Kripke ML. UV irradiationaugments lymphoid malignancies in mice with one functional copy of wild-type p53. Proc Natl Acad Sci U S A98:9790-9795, 2001.

323. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, Garden AS, Benjamin RS. Adultrhabdomyosarcoma: outcome following multimodality treatment. Cancer 95:377-388, 2002.

324. Berrak SG, Ozek MM, Canpolat C, Dagcinar A, Sav A, El-Naggar AK, Langford LA. Association between DNA contentand tumor suppressor gene expression and aggressiveness of atypical teratoid/rhabdoid tumors. Childs Nerv Syst18:485-491, 2002.

325. Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cellcarcinoma. J Urol 168:51-55, 2002.

326. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY. Clinical significance of insulin-likegrowth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796-3802, 2002.

327. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D, Hong WK, Mao L. Cyclin B1 overexpression andresistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62:6414-6417, 2002.

328. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. Differential expression of p53 gene family membersp63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 33:158-164, 2002.

329. El-Naggar AK, Kim HW, Clayman GL, Coombes MM, Le B, Lai S, Zhan F, Luna MA, Hong WK, Lee JJ. Differentialexpression profiling of head and neck squamous carcinoma: significance in their phenotypic and biologicalclassification. Oncogene 21:8206-8219, 2002.

330. Lott ST, Chandler DS, Curley SA, Foster CJ, El-Naggar AK, Frazier M, Strong LC, Lovell M, Killary AM. High frequencyloss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for astepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 62:1952-1955, 2002.

CV Output


331. Frierson HF, Jr, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T, Moskaluk CA, Hampton GM. Largescale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol161:1315-1323, 2002.

332. Choi HR, Batsakis JG, Callender DL, Prieto VG, Luna MA, El-Naggar AK. Molecular analysis of chromosome 16qregions in dermal analogue tumors of salivary glands: a genetic link to dermal cylindroma? Am J Surg Pathol 26:778-783, 2002.

333. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, El-Naggar AK, Lotan R, Lippman SM. Suppression oftype I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 8:2067-2072,2002.

334. Shmulevich I, Hunt K, El-Naggar AK, Taylor E, Ramdas L, Laborde P, Hess KR, Pollock R, Zhang W. Tumor specificgene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer 94:2069-2075,2002.

335. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Jr, Recant W, El-Naggar AK, Stenson K, Lippman SM,Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. JClin Oncol 21:4546-4552, 2003.

336. Papadimitrakopoulou VA, Lui DD, Mao L, Shin DM, El-Naggar AK, Ibarguen H, Lee JJ, Hong WK, Hittelman WN.Biologic correlates of a biochemoprevention trail in advanced upper aerodigestive tract premalignant lesions. CancerEpidemiol Biomarkers Prev 11:1605-1610, 2003.

337. Clark AL, Gillenwater AM, Collier TG, Alizadeh-Naderi R, El-Naggar AK, Richards-Kortum RR. Confocal microscopy forreal-time detection of oral cavity neoplasia. Clin Cancer Res 9:4714-4721, 2003.

338. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ,Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upperaerodigestive tract cancer. J Natl Cancer Inst 95:198-205, 2003.

339. Choi HR, Tucker SA, Huang Z, Gillenwater AM, Luna MA, Batsakis JG, El-Naggar AK. Differential expressions ofcyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.Int J Oncol 22:409-414, 2003.

340. Greenberg JS, El Naggar AK, Mo V, Roberts D, Myers JN. Disparity in pathologic and clinical lymph node staging inoral tongue carcinoma. Implication for therapeutic decision making. Cancer 98:508-515, 2003.

341. Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK, Myers JN. Extent of extracapsular spread: acritical prognosticator in oral tongue cancer. Cancer 97:1464-1470, 2003.

342. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK, Spitz MR, Schiller JT, Wei Q, Sturgis EM.Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: amatched pair analysis. Clin Cancer Res 9:2620-2626, 2003.

343. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, CorreaAM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A,Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, PistersKM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Inductionof p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53(INGN 201) and radiation therapy. Clin Cancer Res 9:93-101, 2003.

344. Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, Clayman GL. Inhibition ofserine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry42:3874-3881, 2003.

345. Jayakumar A, Kang Y, Frederick MJ, Pak SC, Henderson Y, Holton PR, Mitsudo K, Silverman GA, EL-Naggar AK,Bromme D, Clayman GL. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin(SERPINB13): a kinetic analysis. Arch Biochem Biophys 409:367-374, 2003.

346. Biddle DA, Evans HL, Kemp BL, El-Naggar AK, Harvell JD, White WL, Iskandar SS, Prieto VG. Intraparenchymal nevuscell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J SurgPathol 27:673-681, 2003.

347. Barker JL, Jr, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, Clayman G, Rosenthal DI.Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer 98:2322-2328, 2003.

348. MacGregor AR, Batsakis JG, El-Naggar AK. Myofibroblastoma of the larynx: a study of two cases. Head Neck 25:606-611, 2003.

349. Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar AK, Lippman SM, Kripke ML, AnanthaswamyHN. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res9:228-234, 2003.

350. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks NM, Ro JY, Hong WK, Merritt JA, Ahrar K, Alkinson NE, CorreaAM, Dolormente M, Dreiling I, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A,Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, PistersKM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. p53mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. . Int J. Oncol 22:409-414,

CV Output


2003.351. Sabloff B, Munden RF, Melhem AI, El-Naggar AK, Putnam JB, Jr. Radiologic-pathologic conferences of the University

of Texas M. D. Anderson Cancer Center: Extraskeletal osteosarcoma of the pleura. AJR Am J Roentgenol 180:972,2003.

352. Caudell JJ, Ballo MT, Zagars GK, Lewis VO, Weber KL, Lin PP, Marco RA, El-Naggar AK, Benjamin RS, Yasko AW.Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 57:158-165, 2003.

353. Coombes MM, Briggs KL, Bone JR, Clayman GL, El-Naggar AK, Dent SY. Resetting the histone code at CDKN2A inHNSCC by inhibition of DNA methylation. Oncogene 22:8902-8911, 2003.

354. Choi HR, Sturgis EM, Rosenthal DI, Luna MA, Batsakis JG, El-Naggar AK. Sarcomatoid carcinoma of the head andneck: molecular evidence for evolution and progression from conventional squamous cell carcinomas. Am J SurgPathol 27:1216-1220, 2003.

355. Choi HR, Sturgis EM, Rashid A, DeMonte F, Luna MA, Batsakis JG, El-Naggar AK. Sinonasal adenocarcinoma:evidence for histogenetic divergence of the enteric and nonenteric phenotypes. Hum Pathol 34:1101-1107, 2003.

356. Rosenthal, Barker JL, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, Clayman GL, Demonte F, Selek U, Morrison WM,Ang KK, Garden AS:. Sinonasal carcinoma with neuroendocrine differentiation: patterns of failure according tohistologic phenotype. . Int J Radiat Oncol Biol Phys 57:S248-S249, 2003.

357. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O'Neil K, Stover K, El-Naggar AK, Griffin JD, Kirsch IR, KayeFJ. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notchsignaling pathway. Nat Genet 33:208-213, 2003.

358. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar AK, Kies M, Costello R, Summey C, Arquette M, Langer C,Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. ClinCancer Res 10:944-946, 2/2004.

359. Hsu ER, Anslyn EV, Dharmawardhane S, Alizadeh-Naderi R, Aaron JS, Sokolov KV, El-Naggar AK, Gillenwater AM,Richards-Kortum RR. A far-red fluorescent contrast agent to image epidermal growth factor receptor expression.Photochem Photobiol 79:272-279, 2004.

360. Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, Hong WK, Mao L, Oh YW. A novel C/T polymorphismin the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head andneck cancer. Int J Oncol 25:993-999, 2004.

361. Jimenez C, Dang GT, Schultz PN, El-Naggar AK, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF,Cote GJ, Hoff AO. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinasedomain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521-3526, 2004.

362. Li G, Sturgis EM, Wang LE, Chamberlain RM, Spitz MR, El-Naggar AK, Hong WK, Wei Q. Association between theV109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res10:3996-4002, 2004.

363. Li G, Sturgis EM, Wang LE, Chamberlain RM, Amos CI, Spitz MR, El-Naggar AK, Hong WK, Wei Q. Association of ap73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck.Carcinogenesis 25:1911-1916, 2004.

364. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-NaggarAK, Roberts D, Clayman GL, Frederick MJ. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotacticfactor for immature dendritic cells. Cancer Res 64:8262-8270, 2004.

365. Moran CA, Suster S, El-Naggar AK, Luna MA. Carcinomas arising in multilocular thymic cysts of the neck: aclinicopathological study of three cases. Histopathology 44:64-68, 2004.

366. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosomestability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet36:63-68, 2004.

367. El-Naggar AK. Concurrent flow cytometric analysis of DNA and RNA. Methods Mol Biol 263:371-84, 2004.368. Clark AL, Gillenwater A, Alizadeh-Naderi R, El-Naggar AK, Richards-Kortum R. Detection and diagnosis of oral

neoplasia with an optical coherence microscope. J Biomed Opt 9:1271-1280, 2004.369. Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger C, Myers JN, El-Naggar AK, Kellman RM,

Shillitoe EJ, Mollinolo AA, Gutkind JS, Bugge H. Detection of plasminogen activators in oral cancer by laser capturemicrodissection combined with zymography. . Oral Oncology 40:1026-1032, 2004.

370. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK. Differential methylation status oftumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res10:3825-3830, 2004.

371. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN,Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor receptor (EGFR) isoverexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroidcancer. Clin Cancer Res 10:8594-8602, 2004.

372. Jayakumar A, Kang Y, Mitsudo K, Henderson Y, Frederick MJ, Wang M, El-Naggar AK, Marx UC, Briggs K, ClaymanGL. Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit

CV Output


trypsin and subtilisin A. Protein Expr Purif 35:93-101, 2004.373. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-

Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell119:861-872, 2004.

374. Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, Pollock R, Zhang W. Gastrointestinal stromal tumors: overview ofpathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 19:565-574, 2004.

375. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL, El-Naggar AK. Gene expression profiling ofdifferentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586-6597, 2004.

376. Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, Batsakis JG, El-Naggar AK. Gene expression screening ofsalivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn 6:180-190,2004.

377. Yom SS, Rashid A, Rosenthal DI, Elliott DD, Hanna EY, Weber RS, El-Naggar AK. Genetic analysis of sinonasaladenocarcinoma phenotypes: distinct alterations of histogenetic significance . Mod Pathol 18:1-5, 2004.

378. Tai SK, Lee JI, Ang KK, El-Naggar AK, Hassan KA, Liu D, Lee JJ, Ren H, Hong WK, Mao L. Loss of Fhit expression inhead and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res 10:5554-5557, 2004.

379. Fung KM, Diaz EM, Jr, El-Naggar AK, Luna MA. Malignant rhabdoid tumor arising from a pleomorphic adenoma. AnnDiagn Pathol 8:156-161, 2004.

380. Cohn ML, Elliott DD, El-Naggar AK. Metastatic acinic cell carcinoma in a neurofibroma mistaken for carcinosarcoma. .Head Neck 24:76-80, 2004.

381. Choi HR, Roberts DB, Johnigan RH, Sturgis EM, Rosenthal DI, Weber RS, Luna MA, Batsakis JG, El-Naggar AK.Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctivefeatures of biological significance. Am J Surg Pathol 28:1299-1310, 2004.

382. Zhang Z, Shi Q, Wang LE, Sturgis EM, Spitz MR, El-Naggar AK, Hong WK, Wei Q. No Association between hOGG1Ser326Cys polymorphism and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol BiomarkersPrev 13:1081-1083, 2004.

383. Esmaeli B, Ahmadi MA, Youssef A, Diba R, Amato M, Myers JN, Kies M, El-Naggar A. Outcomes in patients withadenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg 20:22-26, 2004.

384. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Jr, Evans DB, GagelRF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS,Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26:716-726, 2004.

385. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation andinterdisciplinary management. Cancer 100:900-905, 2004.

386. Jimenez C, Habra MA, Huang SC, El-Naggar AK, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma andmedullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.J Clin Endocrinol Metab 89:4142-4145, 2004.

387. Barkan GA, El-Naggar AK. Primary synovial sarcoma of the parotid gland. Ann Diagn Pathol 8:233-236, 2004.388. Selek U, Garden AS, Morrison WH, El-Naggar AK, Rosenthal DI, Ang KK. Radiation therapy for early-stage carcinoma

of the oropharynx. Int J Radiat Oncol Biol Phys 59:743-751, 2004.389. Cohn ML, Callender DL, El-Naggar AK. Sebaceous carcinoma ex-pleomorphic adenoma: a rare phenotypic occurrence.

Ann Diagn Pathol 8:224-226, 2004.390. Rosenthal DI, Barker JL, Jr, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, Jr, Clayman GL, Demonte F, Selek U,

Morrison WH, Ang KK, Chao KS, Garden AS. Sinonasal malignancies with neuroendocrine differentiation: patterns offailure according to histologic phenotype. Cancer 101:2567-2573, 2004.

391. El-Naggar AK, Vielh P. Solid tumor DNA content analysis. Methods Mol Biol 263:355-70, 2004.392. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar AK, Lotan R,

Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa)suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10:658-667, 2004.

393. Sudbo J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbo A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF,Reith A. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350:1405-1413,2004.

394. Svistun E, Alizadeh-Naderi R, El-Naggar A, Jacob R, Gillenwater A, Richards-Kortum R. Vision enhancement systemfor detection of oral cavity neoplasia based on autofluorescence. Head Neck 26:205-215, 2004.

395. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, PapadimitrakopoulouVA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104:2430-2436, 2005.

396. Saffari B, Bernstein L, Hong DC, Sullivan-Halley J, Runnebaum IB, Grill HJ, Jones LA, El-Naggar A, Press MF.Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival andresponsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 15:952-963,2005.

397. Jayakumar A, Kang Y, Henderson Y, Mitsudo K, Liu X, Briggs K, Wang M, Frederick MJ, El-Naggar AK, Bebök Z,Clayman GL. Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion,

CV Output


stability, and subcellular distribution. Arch Biochem Biophys 435:89-102, 2005.398. Backous DD, DeMonte F, El-Naggar AK, Wolf P, Weber RS. Craniofacial resection for nonmelanoma skin cancer of the

head and neck. Laryngoscope 115:931-937, 2005.399. Maruya S, Kies MS, Williams M, Myers JN, Weber RS, Batsakis JG, El-Naggar AK. Differential expression of p63

isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications. Hum Pathol 36:821-827,2005.

400. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK. ICAM-5 (telencephalin) gene expression inhead and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol 41:580-588, 2005.

401. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar AK, Bekele BN, MillsGB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther4:1146-1156, 2005.

402. Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss ofE-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103:952-959,2005.

403. Moore BA, Weber RS, Prieto V, El-Naggar AK, Holsinger FC, Zhou X, Lee JJ, Lippman S, Clayman GL. Lymph nodemetastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 115:1561-1567, 2005.

404. Neumann AS, Lyons HJ, Shen H, Liu Z, Shi Q, Sturgis EM, Shete S, Spitz MR, El-Naggar A, Hong WK, Wei Q.Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: acase-control analysis. Int J Cancer 115:131-136, 2005.

405. Gillenwater A, Lewin J, Roberts D, El-Naggar AK. Moderately differentiated neuroendocrine carcinoma (atypicalcarcinoid) of the larynx: a clinically aggressive tumor. Laryngoscope 115:1191-1195, 2005.

406. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS,Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol 23:759-765, 2005.

407. Vadlamudi RK, Balasenthil S, Sahin AA, Kies M, Weber RS, Kumar R, El-Naggar AK. Novel estrogen receptorcoactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.Hum Pathol 36:670-675, 2005.

408. Diaz EM, Johnigan RH, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 27:138-149, 2005.

409. Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primaryhyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblasticosteosarcoma. J Bone Miner Res 20:1562-1568, 2005.

410. Li J, El-Naggar AK, Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoidcystic carcinoma. Cancer 104:771-776, 2005.

411. Baker H, Patel V, Molinolo AA, Shillitoe EJ, Ensley JF, Yoo GH, Meneses-García A, Myers JN, El-Naggar AK, GutkindJS, Hancock WS. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capturemicrodissection and tandem mass spectrometry. Oral Oncol 41:183-199, 2005.

412. Chakravarti N, Saadati HG, El-Naggar AK, Lotan R, Diba RE, Esmaeli B. Retinoid receptor subtypes in sebaceous cellcarcinoma of the eyelid. Ophthal Plast Reconstr Surg 21:292-297, 2005.

413. Schiff BA, Roberts DB, El-Naggar A, Garden AS, Myers JN. Selective vs modified radical neck dissection andpostoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. ArchOtolaryngol Head Neck Surg 131:874-878, 2005.

414. Vielh P, Carton M, Padoy E, de Rycke Y, Klijanienko J, El-Naggar AK, Asselain B. S-phase fraction as an independentprognostic factor of long-term overall survival in patients with early-stage or locally advanced invasive breastcarcinoma. Cancer 105:476-482, 2005.

415. Yom SS, Machtay M, Biel MA, Sinard RJ, El-Naggar AK, Weber RS, Rosenthal DI. Survival impact of plannedrestaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomasof the oropharynx and hypopharynx. Am J Clin Oncol 28:385-392, 2005.

416. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppressesAkt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92:1899-1905, 2005.

417. Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar AK, Yao TP, Khuri FR, Giannakakou P. Thesynergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation andrequires a functional tubulin deacetylase. Cancer Res 65:3883-3893, 2005.

418. Ohshiro K, Rayala SK, Williams MD, Kumar R, El-Naggar AK. Biological role of estrogen receptor beta in salivary glandadenocarcinoma cells. Clin Cancer Res 12:5994-5999, 2006.

419. El-Naggar AK. Clear cell hidradenoma of the skin--a third tumor type with a t(11;19)-associated TORC1-MAML2 genefusion: Genes Chromosomes Cancer. 2005;43:202-205. Adv Anat Pathol 13:80-82, 2006.

420. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN.Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinasesreduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. MolCancer Ther 5:2696-2705, 2006.

CV Output


421. Apisarnthanarax S, Elliott DD, El-Naggar AK, Asper JA, Blanco A, Ang KK, Garden AS, Morrison WH, Rosenthal D,Weber RS, Chao KS. Determining optimal clinical target volume margins in head-and-neck cancer based onmicroscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys 64:678-683, 2006.

422. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN. Dual epidermal growth factor receptor andvascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroidcancer. Clin Cancer Res 12:3425-3434, 2006.

423. Chakravarti N, El-Naggar AK, Lotan R, Anderson J, Diwan AH, Saadati HG, Diba R, Prieto VG, Esmaeli B. Expressionof retinoid receptors in sebaceous cell carcinoma. J Cutan Pathol 33:10-17, 2006.

424. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou X,Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity inretinoid-resistant oral leukoplakia. Clin Cancer Res 12:3109-3114, 2006.

425. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S,Slebos RJ, Yarbrough WG. Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation ofNuclear Factor-{kappa}B Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma.Cancer Res 66:8210-8218, 2006.

426. Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, MyersJN. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nudemouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-465, 2006.

427. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY.Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-inducednegative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12:653-661, 2006.

428. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK.Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12:7353-7358, 2006.

429. Yom SS, Rosenthal DI, El-Naggar AK, Kies MS, Hessel AC. Merkel cell carcinoma of the tongue and head and neckoral mucosal sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:761-768, 2006.

430. Giri U, Ashorn CL, Ramdas L, Stivers DN, Coombes K, El-Naggar AK, Ang KK, Story MD. Molecular signaturesassociated with clinical outcome in patients with high-risk head-and-neck squamous cell carcinoma treated by surgeryand radiation. Int J Radiat Oncol Biol Phys 64:670-677, 2006.

431. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L. Overexpression of podoplanin in oral cancer and itsassociation with poor clinical outcome. Cancer 107:563-569, 2006.

432. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability.Proc Natl Acad Sci U S A 103:19842-19847, 2006.

433. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q. Polymorphisms of FAS and FASligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head andneck. Clin Cancer Res 12:5596-5602, 2006.

434. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM, Myers JN. Presence of malignant tumorcells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx isassociated with poor survival. Eur Arch Otorhinolaryngol 263:313-318, 2006.

435. Hsu ER, Gillenwater AM, Hasan MQ, Williams MD, El-Naggar AK, Richards-Kortum RR. Real-time detection ofepidermal growth factor receptor expression in fresh oral cavity biopsies using a molecular-specific contrast agent. IntJ Cancer 118:3062-3071, 2006.

436. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C,Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cellcarcinoma of the head and neck. Oral Oncol 42:430-439, 2006.

437. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Jack Lee J, Hong WK, Lee HY. The prognostic role of lossof insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239:136-143,2006.

438. Nykter M, Hunt KK, Pollock RE, El-Naggar AK, Taylor E, Shmulevich I, Yli-Harja O, Zhang W. Unsupervised analysisuncovers changes in histopathologic diagnosis in supervised genomic studies. Technol Cancer Res Treat 5:177-182,2006.

439. Williams MD, Hanna EY, El-Naggar AK. Anaplastic ameloblastic fibrosarcoma arising from recurrent ameloblasticfibroma: restricted molecular abnormalities of certain genes to the malignant transformation. Oral Surg Oral Med OralPathol Oral Radiol Endod 104:72-75, 2007.

440. Carlson AL, Gillenwater AM, Williams MD, El-Naggar AK, Richards-Kortum RR. Confocal microscopy and molecular-specific optical contrast agents for the detection of oral neoplasia. Technol Cancer Res Treat 6:361-374, 2007.

441. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK. CRTC1/MAML2 fusion transcript in high grademucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis andbiologic behavior. Genes Chromosomes Cancer 46:708-715, 2007.

442. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differentialexpression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role

CV Output


in therapeutic stratification of patients. Am J Surg Pathol 31:1645-1652, 2007.443. Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS. Effect of initial treatment on disease outcome for

patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 133:546-550, 2007.444. Younes MN, Yigitbasi OG, Yazici YD, Jasser SA, Bucana CD, El-Naggar AK, Mills GB, Myers JN. Effects of the

integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol HeadNeck Surg 133:15-23, 2007.

445. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growthfactor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamouscancer. J Clin Oncol 25:2164-2170, 2007.

446. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W, Trent JC.Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survivalin 105 patients. Cancer 110:2293-2303, 2007.

447. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI.Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromisingCENP-E and CENP-F function. Mol Cancer Ther 6:1317-1328, 2007.

448. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M.Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/akt pathway in thyroid cancer. Clin CancerRes 13:1161-1170, 2007.

449. Li C, Hu Z, Lu J, Liu Z, Wang LE, El-Naggar AK, Sturgis EM, Spitz MR, Wei Q. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.Cancer 110:867-875, 2007.

450. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head andneck squamous carcinomas. Hum Pathol 38:1553-1562, 2007.

451. Price ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, Hunt KK, Pollock RE, Hood L, Shmulevich I, Zhang W. Highlyaccurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl AcadSci U S A 104:3414-3419, 2007.

452. Ohshiro K, Rayala SK, Kondo S, Gaur A, Vadlamudi RK, El-Naggar AK, Kumar R. Identifying the estrogen receptorcoactivator PELP1 in autophagosomes. Cancer Res 67:8164-8171, 2007.

453. Li D, Wang LE, Chang P, El-Naggar AK, Sturgis EM, Wei Q. In vitro benzo[a]pyrene diol epoxide-induced DNA adductsand risk of squamous cell carcinoma of head and neck. Cancer Res 67:5628-5634, 2007.

454. Xiong P, Hu Z, Li C, Wang LE, El-Naggar AK, Sturgis EM, Wei Q. In vitro benzo[a]pyrene diol epoxide-induced DNAdamage and chromosomal aberrations in primary lymphocytes, smoking, and risk of squamous cell carcinoma of thehead and neck. Int J Cancer 121:2735-2740, 2007.

455. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target inhead and neck cancer. Clin Cancer Res 13:4291-4299, 2007.

456. Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D, Jerry DJ, Blackburn AC, Peltz G, Amos CI, Lozano G.Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 18:300-309, 2007.

457. El-Naggar AK. Pathobiology of head and neck squamous tumorigenesis. Curr Cancer Drug Targets 7:606-612, 2007.458. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, Wei Q. Polymorphic TP53BP1 and TP53 gene

interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 13:4300-4305,2007.

459. An J, Liu Z, Hu Z, Li G, Wang LE, Sturgis EM, El-Naggar AK, Spitz MR, Wei Q. Potentially functional single nucleotidepolymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck.Cancer Epidemiol Biomarkers Prev 16:1633-1638, 2007.

460. Ohshiro K, Rosenthal DI, Koomen JM, Streckfus CF, Chambers M, Kobayashi R, El-Naggar AK. Pre-analytic salivaprocessing affect proteomic results and biomarker screening of head and neck squamous carcinoma. Int J Oncol30:743-749, 2007.

461. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG,Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associatedwith risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res 13:6532-6539, 2007.

462. Chen K, Hu Z, Wang LE, Sturgis EM, El-Naggar AK, Zhang W, Wei Q. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head andneck. Carcinogenesis 28:2008-2012, 2007.

463. Lupinetti AD, Roberts DB, Williams MD, Kupferman ME, Rosenthal DI, Demonte F, El-Naggar A, Weber RS, Hanna EY.Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer 110:2726-2731, 2007.

464. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN. Sorafenib inhibits theangiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6:1785-1792, 2007.

465. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis 29:2120-2125. e-Pub

CV Output


8/2008.466. Zhang N, Ge G, Meyer R, Sethi S, Basu D, Pradhan S, Zhao YJ, Li XN, Cai WW, El-Naggar AK, Baladandayuthapani

V, Kittrell FS, Rao PH, Medina D, Pati D. Overexpression of Separase induces aneuploidy and mammarytumorigenesis. Proc Natl Acad Sci U S A 105:13033-13038. e-Pub 8/2008. PMCID: PMC2529090.

467. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL. Aurora kinase A inhibition and paclitaxel as targetedcombination therapy for head and neck squamous cell carcinoma. Head Neck. e-Pub 12/2008.

468. Nitin N, Carlson AL, Muldoon T, El-Naggar AK, Gillenwater A, Richards-Kortum R. Molecular imaging of glucose uptakein oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int J Cancer. e-Pub 12/2008.

469. Gelbard A, Kupferman ME, Jasser SA, Chen W, El-Naggar AK, Myers JN, Hanna EY. An orthotopic murine model ofsinonasal malignancy. Clin Cancer Res 14:7348-7357, 2008.

470. Yildirim G, Gillenwater AM, Ordonez NG, Garden AS, El-Naggar AK. Concurrent epithelioid malignant peripheral nervesheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. Head Neck 30:675-679, 2008.

471. Mishra A, El-Naggar AK, DeMonte F, Hanna EY. Endodermal sinus tumor of the paranasal sinuses. Head Neck30:539-543, 2008.

472. Santarpia L, El-Naggar AK, Sherman SI, Hymes SR, Gagel RF, Shaw S, Sarlis NJ. Four patients with cutaneousmetastases from medullary thyroid cancer. Thyroid 18:901-905, 2008.

473. Zhai X, Zhao H, Liu Z, Wang LE, El-Naggar AK, Sturgis EM, Wei Q. Functional variants of the NEIL1 and NEIL2 genesand risk and progression of squamous cell carcinoma of the oral cavity and oropharynx. Clin Cancer Res 14:4345-4352, 2008.

474. Ye L, Santarpia L, Cote GJ, El-Naggar AK, Gagel RF. High resolution array-comparative genomic hybridization profilingreveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin EndocrinolMetab 93:4367-4372, 2008. e-Pub 9/2008.

475. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Medullary thyroid cancer: targeting the RETkinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006, 2008. e-Pub 4/2008.

476. Pavlova I, Weber CR, Schwarz RA, Williams M, El-Naggar A, Gillenwater A, Richards-Kortum R. Monte Carlo model todescribe depth selective fluorescence spectra of epithelial tissue: applications for diagnosis of oral precancer. J BiomedOpt 13:064012, 2008. PMCID: PMC2615394.

477. Roblyer D, Richards-Kortum R, Sokolov K, El-Naggar AK, Williams MD, Kurachi C, Gillenwater AM. Multispectral opticalimaging device for in vivo detection of oral neoplasia. J Biomed Opt 13:024019, Mar-Apr, 2008.

478. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, AngKK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112:2698-2709, 2008.

479. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, AtwellA, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oralpremalignant lesions. Clin Cancer Res 14:2095-2101, 2008.

480. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM,Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-360,2008.

481. Chambers MS, Tomsett KL, Artopoulou II, Garden AS, El-Naggar AK, Martin JW, Keene HJ. Salivary flow ratesmeasured during radiation therapy in head and neck cancer patients: a pilot study assessing salivary sedimentformation. J Prosthet Dent 100:142-146, 2008.

482. Smith SL, Hessel AC, Luna MA, Malpica A, Rosenthal DI, El-Naggar AK. Sinonasal teratocarcinosarcoma of the headand neck: a report of 10 patients treated at a single institution and comparison with reported series. Arch OtolaryngolHead Neck Surg 134:592-595, 2008.

483. Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. Small molecule c-MET inhibitor PHA665752: Effect on cellgrowth and motility in papillary thyroid carcinoma. Head Neck 30:991-1000, 2008.

484. Pavlova I, Williams M, El-Naggar A, Richards-Kortum R, Gillenwater A. Understanding the biological basis ofautofluorescence imaging for oral cancer detection: high-resolution fluorescence microscopy in viable tissue. ClinCancer Res 14:2396-2404, 2008.

485. Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK, Myers JN. Vandetanibinhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 14:5081-5089, 2008.

486. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK, Richards-Kortum R, Gillenwater AM.Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 115:1669-1679, 1/2009.

487. Chakravarty G, Santillan AA, Galer C, Adams HP, El-Naggar AK, Jasser SA, Mohsin S, Mondal D, Clayman GL, MyersJN. Phosphorylated Insulin like growth factor-I receptor expression and its clinico-pathological significance in histologicsubtypes of human thyroid cancer. Exp Biol Med (Maywood), 1/2009. e-Pub 1/2009.

488. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB,Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients withrecurrent papillary thyroid carcinoma. Head Neck. e-Pub 4/2009.

489. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung

CV Output


K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, HafftyB, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independentpredictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068. e-Pub 5/2009.PMCID: PMC2673042.

490. Lu J, Hu Z, Wei S, Wang LE, Liu Z, El-Naggar AK, Sturgis EM, Wei Q. A Novel Functional Variant (-842G>C) in thePIN1 Promoter Contributes to Decreased Risk of Squamous Cell Carcinoma of the Head and Neck by Diminishing thePromoter Activity. Carcinogenesis. e-Pub 7/2009.

491. Saba NF, Choi M, Muller S, Shin HJ, Tighiouart M, Papadimitrakopoulou VA, El-Naggar AK, Khuri FR, Chen ZG, ShinDM. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. CancerPrev Res (Phila Pa) 2(9):823-9, 9/2009. e-Pub 9/2009.

492. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS,Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R. Phase I trial of a combination of the multikinaseinhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res15(22):7061-8, 11/2009. e-Pub 11/2009. PMCID: PMC2784003.

493. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM,Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients withhigh-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2(11):931-41, 11/2009.

494. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngealpremalignancy patients. Cancer Prev Res (Phila Pa) 2:14-21, 2009.

495. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, LeeJJ, El-Naggar AK, Hong WK, Shin DM, Khuri FR. Durable Long-Term Remission With Chemotherapy Alone for StageII to IV Laryngeal Cancer. J Clin Oncol. e-Pub 2009.

496. Upile T, Jerjes W, Sterenborg HJ, El-Naggar AK, Sandison A, Witjes MJ, Biel MA, Bigio I, Wong BJ, Gillenwater A,Macrobert AJ, Robinson DJ, Betz CS, Stepp H, Bolotine L, McKenzie G, Mosse CA, Barr H, Chen Z, Berg K, D'CruzAK, Stone N, Kendall C, Fisher S, Leunig A, Olivo M, Richards-Kortum R, Soo KC, Bagnato V, Choo-Smith LP,Svanberg K, Tan IB, Wilson BC, Wolfsen H, Yodh AG, Hopper C. Head & neck optical diagnostics: vision of the futureof surgery. Head Neck Oncol 1(1):25, 2009. PMCID: PMC2720388.

497. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL. High rate ofBRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491, 2009.

498. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E,Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction chemotherapy andcetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospectivetrial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.

499. Wang LE, Hu Z, Sturgis EM, Spitz MR, Strom SS, Amos CI, Guo Z, Qiao Y, Gillenwater AM, Myers JN, Clayman GL,Weber RS, El-Naggar AK, Mao L, Lippman SM, Hong WK, Wei Q. Reduced DNA repair capacity for removing tobaccocarcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. ClinCancer Res 16(2):764-74, 1/2010. e-Pub 1/2010.

500. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkBinduces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. e-Pub 1/2010.

501. Li C, Lu J, Liu Z, Wang LE, Zhao H, El-Naggar AK, Sturgis EM, Wei Q. The six-nucleotide deletion/insertion variant inthe CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. CancerPrev Res (Phila Pa) 3(2):246-53, 2/2010. e-Pub 1/2010. PMCID: PMC2818282.

502. Moreno MA, Roberts DB, Kupferman ME, Demonte F, El-Naggar AK, Williams M, Rosenthal DS, Hanna EY. Mucosalmelanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center.Cancer. e-Pub 3/2010.

503. Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, ElNaggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN. Sentinel lymph nodebiopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospectivemulti-institutional trial. J Clin Oncol 28(8):1395-400, 3/2010. e-Pub 2/2010.

504. Wei S, Liu Z, Zhao H, Niu J, Wang LE, El-Naggar AK, Sturgis EM, Wei Q. A single nucleotide polymorphism in thealcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk ofsquamous cell carcinoma of the head and neck. Cancer 116(12):2984-92, 6/2010. PMCID: PMC2891145.

505. Liu Z, Li G, Wei S, Niu J, El-Naggar AK, Sturgis EM, Wei Q. Genetic variants in selected pre-microRNA genes and therisk of squamous cell carcinoma of the head and neck. Cancer. e-Pub 6/2010.

506. Hessel AC, Moreno MA, Hanna EY, Roberts DB, Lewin JS, El-Naggar AK, Rosenthal DI, Weber RS. Compliance withquality assurance measures in patients treated for early oral tongue cancer. Cancer 116(14):3408-16, 7/2010.

507. Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, Weber RS, Caulin C, El-Naggar AK. Comprehensive Analysis ofthe MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability and Clinicopathological

CV Output


Significance. Clin Cancer Res 16(19):4722-31, 10/2010. e-Pub 8/2010.508. Lo EJ, Bell D, Woo JS, Li G, Hanna EY, El-Naggar AK, Sturgis EM. Human papillomavirus and WHO type I

nasopharyngeal carcinoma. Laryngoscope 120(10):1990-7, 10/2010. e-Pub 9/2010.509. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KS, Schwartz DL,

Chronowski GM, El-Naggar AK, Garden AS. Intensity-Modulated Radiotherapy for Cervical Node Squamous CellCarcinoma Metastases from Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes andPatterns of Failure. Int J Radiat Oncol Biol Phys 78(4):1005-10, 11/2010. e-Pub 3/2010.

510. Bell D, Holsinger CF, El-Naggar AK. CRTC1/MAML2 fusion transcript in central mucoepidermoid carcinoma ofmandible--diagnostic and histogenetic implications. Ann Diagn Pathol 14(6):396-401, 12/2010.

511. Ryan JT, El-Naggar AK, Huh W, Hanna EY, Weber RS, Kupferman ME. Primacy of surgery in the management ofmucoepidermoid carcinoma in children. Head Neck. e-Pub 1/2011.

512. Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA, Ludwig DL, El-Naggar AK, Weber RS, MyersJN. Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction ofangiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 33(2):189-98, 2/2011. PMCID:PMC3010504.

513. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK,Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF, Calvert VS, Fodale V, Wang J, Weber RS.Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am JPathol 178(2):548-71, 2/2011.

514. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, ElNaggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RETkinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitortipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 4/2011. e-Pub2/2011. PMCID: PMC3070247.

515. Devaney KO, Ferlito A, Rinaldo A, El-Naggar AK, Barnes L. Verrucous carcinoma (carcinoma cuniculatum) of the headand neck: what do we know now that we did not know a decade ago? Eur Arch Otorhinolaryngol 268(4):477-80,4/2011. e-Pub 2/2011.

516. Niu J, Huang YJ, Wei S, Liu Z, Wang LE, Chang S, Chamberlain RM, El-Naggar AK, Sturgis EM, Wei Q. Associationbetween a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk. Head Neck33(5):650-60, 5/2011. e-Pub 10/2010. PMCID: PMC3023825.

517. Ismaiel AA, Ghaly MF, El-Naggar AK. Milk kefir: ultrastructure, antimicrobial activity and efficacy on aflatoxin B1production by Aspergillus flavus. Curr Microbiol 62(5):1602-9, 5/2011. e-Pub 2/2011.

518. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT,Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.Cancer 117(10):2112-9, 5/2011. e-Pub 11/2010. PMCID: PMC3117018.

519. Mitani Y, Li J, Weber RS, Lippman SL, Flores ER, Caulin C, El-Naggar AK. Expression and Regulation of the ?N andTAp63 Isoforms in Salivary Gland Tumorigenesis Clinical and Experimental Findings. Am J Pathol 179(1):391-9,7/2011. e-Pub 5/2011. PMCID: PMC3123859.

520. Williams MD, Zhang L, Elliott DD, Perrier ND, Lozano G, Clayman GL, El-Naggar AK. Differential gene expressionprofiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol 42(9):1213-20, 9/2011. e-Pub 3/2011.PMCID: PMC3156288.

521. Karpowicz MK, Shalmon B, Molberg KH, El-Naggar AK. Melanoma in a carcinoma ex pleomorphic adenoma of theparotid gland: a case report and putative histogenesis. Hum Pathol 42(9):1355-8, 9/2011. e-Pub 3/2011.

522. Zevallos JP, Jain KS, Roberts D, El-Naggar A, Hanna EY, Kupferman ME. Sinonasal malignancies in children: a 10-year, single-institutional review. Laryngoscope 121(9):2001-3, 9/2011. e-Pub 7/2011.

523. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, StephensPJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J,Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC,Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR,Campbell PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. SomaticSF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384-95, 10/2011. e-Pub 9/2011.PMCID: PMC3322589.

524. Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY. Akt/mTOR counteract the antitumor activities ofcixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther 10(12):2437-48,12/2011. e-Pub 10/2011. PMCID: PMC3237768.

525. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C. Gain-of-function mutant p53 but not p53 deletion promoteshead and neck cancer progression in response to oncogenic K-ras. J Pathol 225(4):479-89, 12/2011. e-Pub 9/2011.

526. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G.Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168-75, 12/2011. e-Pub 10/2011. PMCID:

CV Output


PMC3320147.527. Upile T, Jerjes WK, Sterenborg HJ, Wong BJ, El-Naggar AK, Ilgner JF, Sandison A, Witjes MJ, Biel MA, van Veen R,

Hamdoon Z, Gillenwater A, Mosse CA, Robinson DJ, Betz CS, Stepp H, Bolotine L, McKenzie G, Barr H, Chen Z, BergK, D'Cruz AK, Sudhoff H, Stone N, Kendall C, Fisher S, Macrobert AJ, Leunig A, Olivo M, Richards-Kortum R, Soo KC,Bagnato V, Choo-Smith LP, Svanberg K, Tan IB, Wilson BC, Wolfsen H, Bigio I, Yodh AG, Hopper C. At the frontiersof surgery: review. Head Neck Oncol 3(1):7, 2011. e-Pub 2/2011. PMCID: PMC3048561.

528. Gomez-Rivera F, El-Naggar AK, Guha-Thakurta N, Kupferman ME. Rheumatoid arthritis mimicking metastaticsquamous cell carcinoma. Head Neck Oncol 3:26, 2011. e-Pub 5/2011. PMCID: PMC3118955.

529. Likhacheva A, Rosenthal DI, Hanna E, Kupferman M, Demonte F, El-Naggar AK. Sinonasal neuroendocrine carcinoma:impact of differentiation status on response and outcome. Head Neck Oncol 3:32, 2011. e-Pub 7/2011. PMCID:PMC3154852.

530. Jerjes WK, Upile T, Wong BJ, Betz CS, Sterenborg HJ, Witjes MJ, Berg K, van Veen R, Biel MA, El-Naggar AK, MosseCA, Olivo M, Richards-Kortum R, Robinson DJ, Rosen J, Yodh AG, Kendall C, Ilgner JF, Amelink A, Bagnato V, BarrH, Bolotine L, Bigio I, Chen Z, Choo-Smith LP, D'Cruz AK, Gillenwater A, Leunig A, MacRobert AJ, McKenzie G,Sandison A, Soo KC, Stepp H, Stone N, Svanberg K, Tan IB, Wilson BC, Wolfsen H, Hopper C. The future of medicaldiagnostics: review paper. Head Neck Oncol 3:38, 2011. e-Pub 8/2011. PMCID: PMC3180646.

531. Galer C, Santillan AA, Chelius D, Huh W, El-Naggar A, Hanna E, Weber RS, Kupferman ME. Minor salivary glandmalignancies in the pediatric population. Head Neck. e-Pub 1/2012.

532. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. ClinCancer Res 18(1):127-39, 1/2012. e-Pub 11/2011. PMCID: PMC3251692.

533. Bell D, Myers J, Rao PH, El-Naggar AK. t(3;8) as the sole chromosomal abnormality in a myoepithelial carcinoma expleomorphic adenoma: A putative progression event. Head Neck. e-Pub 1/2012.

534. Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar AK, Myers JN. Early postoperative epidermal growth factorreceptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.Head Neck. e-Pub 2/2012.

535. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA,Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. ClinCancer Res 18(5):1435-46, 3/2012. e-Pub 1/2012.

536. Xu L, Li G, Wei Q, El-Naggar AK, Sturgis EM. Family history of cancer and risk of sporadic differentiated thyroidcarcinoma. Cancer 118(5):1228-35, 3/2012. e-Pub 7/2011. PMCID: PMC3208119.

537. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A,Badoual C, Fridman WH, White JM, Hadden JW. Increased lymphocyte infiltration in patients with head and neckcancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 61(6):771-82, 6/2012. e-Pub11/2011.

538. Burch-Smith R, Ordonez NG, Ginsberg LE, Ater JL, El Naggar AK. Oral extragonadal yolk sac tumor in a patient withAicardi syndrome: putative origin and differential diagnosis. Hum Pathol 43(6):939-42, 6/2012. e-Pub 1/2012.

539. Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-NaggarAK, Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome inbreast cancer. Cancer Cell 21(6):793-806, 6/2012. PMCID: PMC3376352.

540. Bhayani MK, Yener M, El-Naggar A, Garden A, Hanna EY, Weber RS, Kupferman ME. Prognosis and risk factors forearly-stage adenoid cystic carcinoma of the major salivary glands. Cancer 118(11):2872-8, 6/2012. e-Pub 10/2011.

541. Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM. A comparison of the demographics, clinical features, and survival ofpatients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within theSurveillance, Epidemiology, and End Results registry. Cancer 118(16):3945-53, 8/2012. e-Pub 12/2011. PMCID:PMC3412946.

542. McHugh CH, Roberts DB, El-Naggar AK, Hanna EY, Garden AS, Kies MS, Weber RS, Kupferman ME. Prognosticfactors in mucoepidermoid carcinoma of the salivary glands. Cancer 118(16):3928-36, 8/2012. e-Pub 12/2011.

543. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM.Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in youngadults. Head Neck 34(9):1255-62, 9/2012. e-Pub 10/2011.

544. Gillenwater AM, Frank SJ, Fatani H, El-Naggar AK. Primary intestinal-like adenocarcinoma of major salivary glands: 2instances of previously undocumented phenotype. Head Neck. e-Pub 10/2012.

545. Guan X, Sturgis EM, Song X, Liu Z, El-Naggar AK, Wei Q, Li G. Pre-microRNA variants predict HPV16-positive tumorsand survival in patients with squamous cell carcinoma of the oropharynx. Cancer Lett. e-Pub 12/2012.

546. Gelbard A, Hale KS, Takahashi Y, Davies M, Kupferman ME, El-Naggar AK, Myers JN, Hanna EY. Molecular profilingof sinonasal undifferentiated carcinoma. Head Neck. e-Pub 4/2013.

547. Zhang L, Mitani Y, Caulin C, Rao PH, Kies MS, Saintigny P, Zhang N, Weber RS, Lippman SM, El-Naggar AK. Detailedgenome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenesof potential clinical significance. Am J Pathol 182(6):2048-57, 6/2013. e-Pub 4/2013. PMCID: PMC3668022.

CV Output


548. Ow TJ, Hanna EY, Roberts DB, Levine NB, El-Naggar AK, Rosenthal DI, Demonte F, Kupferman ME. Optimization oflong-term outcomes for patients with esthesioneuroblastoma. Head Neck. e-Pub 6/2013.

549. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K,Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN,Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ. Integrative genomic characterization of oralsquamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3(7):770-81, 7/2013. e-Pub 4/2013.

550. Millare GG, Guha-Thakurta N, Sturgis EM, El-Naggar AK, Debnam JM. Imaging Findings of Head and NeckDermatofibrosarcoma Protuberans. AJNR Am J Neuroradiol. e-Pub 8/2013.

551. El-Naggar AK, Kaye FJ, Stenman G. The 3rd Salivary Gland Tumor Workshop meeting report. Head Neck 35(8):1057-60, 8/2013.

552. Neskey DM, Klein JD, Hicks S, Garden AS, Bell DM, El-Naggar AK, Kies MS, Weber RS, Kupferman ME. PrognosticFactors Associated With Decreased Survival in Patients With Acinic Cell Carcinoma. JAMA Otolaryngol Head NeckSurg. e-Pub 9/2013.

553. Gillenwater AM, Vigneswaran N, Fatani H, Saintigny P, El-Naggar AK. Proliferative verrucous leukoplakia (PVL):Recognition and differentiation from conventional leukoplakia and mimics! Head Neck. e-Pub 9/2013.

554. Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, Trimarchi F, El-Naggar AK, Gagel RF. A miRNA signature associated with human metastatic medullary thyroid carcinoma. EndocrRelat Cancer 20(6):809-23, 2013. e-Pub 10/2013.

555. Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM, El-Naggar AK. MicroRNA profiling of salivaryadenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome. PLoS One 8(6):e66778, 2013. e-Pub 6/2013. PMCID: PMC3692530.

Invited Articles1. El-Naggar AK. DNA flow cytometric analysis in the assessment of soft tissue neoplams. Cancer Bulletin 45:24-28, 1993.2. Batsakis JG, Sneige N, El-Naggar AK. Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer.

Cancer 71:2151-2153, 1993.3. Klijanienko, Janot F, deBraud F, Russo A, Pignon JP, El-Naggar AK, Luboinski B, Cvitkovic E. Clinicopathological

Grading in Head and Neck Squamous Cell Carcinoma (HNSCC). A prospective analysis of 108 Patients TreatedCuratively. XVI International Cancer Congress:939-942, 1994.

4. El-Naggar AK. MTS1/p16 INKA (CDKN2) Gene: The jury is still out. Advances in Anatomic Pathology 4:227-229, 1995.5. Batsakis JG, El-Naggar AK. p53: Fifteen years after discovery. Advance in Anatomic Pathology 2:71-88, 1995.6. Suarez P, Batsakis JG, El-Naggar AK. Leukoplakia: Still a gallimaufry or is progress being made? - A Review.

Advances in Anatomic Pathology 5:137-155, 1998.7. Batsakis JG, Suarez P, El-Naggar. Mucosal melanomas of the head and neck. Annals of Otology, Rhinology &

Laryngology 107:626-630, 1998.8. Soria J-C, Vielh J, El-Naggar AK. Telomerase activity in cancer: A magic bullet or a mirage? Advances in Anatomic

Pathology 5:86-94, 1998.9. Klijanienko J, Vielh P, Batsakis JG, El-Naggar, Jelen M, Piekarski JG. Salivary gland tumours. Monogr Clin Cytol 15:1-

138, 2000.10. El-Naggar AK. Methods in molecular surgical pathology. Semin Siagn Pathol 19:56-71, 2002.11. Batsakis JG, Medeiros JL, Luna MA, El-Naggar AK. Plasma cell dyscrasias and the head and neck. Ann Diagn Pathol

6:129-140, 2002.12. El-Naggar AK. News in Brief: Mitochondrial DNA mutations in cancer diagnosis? Advances in Anatomic Pathology

10:50-51, 2003.13. Bell D, Zhao YJ, Rao PH, Weber RS, El-Naggar AK. Translocation t(6;14) as the sole chromosomal abnormality in

adenoid cystic carcinoma of the base of tongue. Head Neck Pathol 1(2):165-8, 12/2007. e-Pub 10/2007. PMCID:PMC2807514.

14. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with genderdifferences in survival. Oncogene 26:6896-6904, 2007.

15. Naqvi J, Ordonez NG, Luna MA, Williams MD, Weber RS, El-Naggar AK. Epithelioid hemangioendothelioma of thehead and neck: role of podoplanin in the differential diagnosis. Head Neck Pathol 2(1):25-30, 3/2008. e-Pub 10/2007.PMCID: PMC2807604.

16. Maitland KC, Gillenwater AM, Williams MD, El-Naggar AK, Descour MR, Richards-Kortum RR. In vivo imaging of oralneoplasia using a miniaturized fiber optic confocal reflectance microscope. Oral Oncol, 4/2008. e-Pub 4/2008.

17. Bell D, Luna MA, Weber RS, Kaye FJ, El-Naggar AK. CRTC1/MAML2 fusion transcript in Warthin's tumor andmucoepidermoid carcinoma: evidence for a common genetic association. Genes Chromosomes Cancer 47:309-314,2008.

18. Rao PH, Roberts D, Zhao YJ, Bell D, Harris CP, Weber RS, El-Naggar AK. Deletion of 1p32-p36 is the most frequentgenetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res14:5181-5187, 2008.

19. Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Delivery of cytoplasmic proteins to autophagosomes. Autophagy 4:104-

CV Output


106, 2008. e-Pub 10/2007.20. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick

GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Srcactivation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112:2088-2100, 2008.

21. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK. Growth factor receptorsexpression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol 39:15-20, 2008.e-Pub 10/2007.

22. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities.Mol Cancer Res 6:947-954, 2008.

23. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284, 2008. e-Pub 11/2007.

24. Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK. Quantitative PromoterHypermethylation Analysis of Cancer-Related Genes in Salivary Gland Carcinomas: Comparison with Methylation-Specific PCR Technique and Clinical Significance. Clin Cancer Res 14:2664-2672, 2008.

25. Santarpia L, Sherman SI, Marabotti A, Clayman GL, El-Naggar AK. Detection and molecular characterization of a novelBRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. e-Pub 2/2009.

26. Roblyer D, Kurachi C, Stepanek V, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-Kortum R. Objectivedetection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila Pa) 2(5):423-31.e-Pub 4/2009. PMCID: PMC2719708.

27. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, Richards-Kortum RR. Optical molecular imaging ofepidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia 11(6):542-51, 6/2009.PMCID: PMC2685443.

28. Mithani SK, Shao C, Tan M, Smith IM, Califano JA, El-Naggar AK, Ha PK. Mitochondrial mutations in adenoid cysticcarcinoma of the salivary glands. PLoS One 4(12):e8493, 2009. PMCID: PMC2795173.

29. Cordes B, Williams MD, Tirado Y, Bell D, Rosenthal DI, Al-Dhahri SF, Hanna EY, El-Naggar AK. Molecular andphenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis andclassification. Hum Pathol 40:283-292, 2009.

30. Nash JW, Hessel AC, Vigneswaran N, El-Naggar AK. Collagenous myofibroblastic tumor of the mandible: case report ofa unique locally aggressive neoplasm. Head Neck Pathol 4(1):44-8, 3/2010. e-Pub 12/2009. PMCID: PMC2825531.

31. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK. Genetic and expression analysis of HER-2 andEGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16(8):2266-74,4/2010. e-Pub 4/2010.

32. Senna MM, Salmieri S, El-Naggar AW, Safrany A, Lacroix M. Improving the compatibility of zein/poly(vinyl alcohol)blends by gamma irradiation and graft copolymerization of acrylic acid. J Agric Food Chem 58(7):4470-6, 4/2010.

33. Santarpia L, Myers JN, Sherman SI, Trimarchi F, Clayman GL, El-Naggar AK. Genetic alterations in theRAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicularvariant of papillary thyroid carcinoma. Cancer 116(12):2974-83, 6/2010.

34. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK,Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serumsignature of hypoxia-regulated factors is associated with progression after induction therapy in head and necksquamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.

35. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH,Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptorexpression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3(7):800-9, 7/2010. e-Pub6/2010. PMCID: PMC2900459.

36. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicyclechemotherapy in patients with cancer: a randomized trial. Ann Intern Med 153(6):358-67, 9/2010.

37. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba I,Flores ER. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 467(7318):986-90, 10/2010. PMCID: PMC3055799.

38. Roblyer D, Kurachi C, Stepanek V, Schwarz RA, Williams MD, El-Naggar AK, Lee JJ, Gillenwater AM, Richards-KortumR. Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objectivediscrimination of oral neoplasia. J Biomed Opt 15(6):066017, Nov-Dec, 11/2010. PMCID: PMC3013151.

39. Bell D, Roberts D, Kies M, Rao P, Weber RS, El-Naggar AK. Cell type-dependent biomarker expression in adenoidcystic carcinoma: biologic and therapeutic implications. Cancer 116(24):5749-56, 12/2010. e-Pub 9/2010.

40. Liu Z, Liu D, Bojdani E, El-Naggar AK, Vasko V, Xing M. IQGAP1 plays an important role in the invasiveness of thyroidcancer. Clin Cancer Res 16(24):6009-18, 12/2010. e-Pub 10/2010. PMCID: PMC3005072.

CV Output


41. Lewis CM, Hessel AC, Roberts DB, Guo YZ, Holsinger FC, Ginsberg LE, El-Naggar AK, Weber RS. Prereferral headand neck cancer treatment: compliance with national comprehensive cancer network treatment guidelines. ArchOtolaryngol Head Neck Surg 136(12):1205-11, 12/2010.

42. Lo EJ, Bell D, Woo J, Li G, Hanna EY, El-Naggar AK, Sturgis EM. Human papillomavirus & WHO type Inasopharyngeal carcinoma. Laryngoscope 120 Suppl 4:S185, 2010.

43. Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L.Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 4(2):218-29, 2/2011.PMCID: PMC3074595.

44. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, LozanoG. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with ap53 missense mutation. J Clin Invest 121(3):893-904, 3/2011. PMCID: PMC3049366.

45. Bell A, Bell D, Weber RS, El-Naggar AK. CpG island methylation profiling in human salivary gland adenoid cysticcarcinoma. Cancer 117(13):2898-909, 7/2011. e-Pub 1/2011. PMCID: PMC3123690.

46. Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1-a novel biomarker inhuman salivary gland adenoid cystic carcinoma*. Cancer. e-Pub 7/2011.

47. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivityand metastasis suppression in head and neck squamous cell carcinoma. Oncogene 30(28):3163-73, 7/2011. e-Pub3/2011. PMCID: PMC3136629.

48. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N,El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, WestraWH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA,Kinzler KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations inNOTCH1. Science 333(6046):1154-7, 8/2011. e-Pub 7/2011. PMCID: PMC3162986.

49. Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao YJ, Zhang L, Mitani M, Weber RS, Lippman SM, CaulinC, El-Naggar AK. Novel Chromosomal Rearrangements and breakpoints at the t(6;9) in Salivary Adenoid CysticCarcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res17(22):7003-7014. e-Pub 10/2011.

50. Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, Patra S, Mohanty B, El-Naggar AK, Mandal M. Expressionsof CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers byimmunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol 9(3):187-99, 2011.

51. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. ExpertOpin Ther Targets. 16(1):103-19. e-Pub 1/2012.

52. Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, El-Naggar AK, Ginsberg LE, Rosenthal DI, GlissonBS, Morrison WH, Weber RS, Garden AS. Prediction of neck dissection requirement after definitive radiotherapy forhead-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 82(3):e367-74, 3/2012.

53. Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY. Biology and management of salivary gland cancers. SeminRadiat Oncol 22(3):245-53, 7/2012.

54. Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS,Johnson FM, El-Naggar AK, Myers JN. Residual nodal disease in patients with advanced-stage oropharyngealsquamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association withlocoregional recurrence, distant metastasis, and decreased survival. Head Neck. e-Pub 9/2012.

55. Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK,Yarbrough WG. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasivebehavior. Oncogene. e-Pub 10/2012.

Editorials1. El-Naggar AK, Batskis JG. Carcinoid tumor of the larynx: A critical review of the literature. ORL 53:188-193, 1991.2. Connelly JH, Robey-Cafferty SS, El-Naggar AK, Cleary KR. Exophytic signet-ring cell carcinoma of the colorectum.

Arch Pathol Lab Med 115:134-136, 1991.3. El-Naggar AK. Clinical relevance of flow cytometric analysis in cancer. Cancer Journal 5:321-327, 1992.4. El-Naggar AK. Flow cytometry in the assessment of human solid neoplasms. Ann Saudi Med 12:331-333, 1992.5. El-Naggar AK. Laryngeal neuroendocrine neoplasms. Victims of semantics. Path Lab Med 116:237-238, 1992.6. El-Naggar AK. Commentary: DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast

carcinoma. Breast Diseases 4:27-28, 1993.7. Klijanienko J, Janot F, deBraud F, Russo A, Pignon JP, El-naggar AK, Luboinski B, Cvitkovic E. Clinicopathological

Grading in Head and Neck Squamosu Cell Carcinoma (HNSCC). A prospective analysis of 108 patients treatedcuratively. XVI International Cancer Congress:939-942, 1994.

8. El-Naggar AK. Commentary: Apoptosis suppressing protein bcl-2 is expressed in well-differentated breast carcinomawith favorable prognosis. Breast Diseases 7:160-161, 1996.

9. El-Naggar AK. Commentary: Bcl-2 expression in the spectrum of pre-invasive breast lesions. Breast Diseases 3:251-252, 1996.

CV Output


10. El-Naggar AK. Commentary: Different risk group in node-negative breast cancer: Prognostic value ofcytophotometrically assessed DNA, morphometry and texture. Breast Diseases 7:161-162, 1996.

11. El-Naggar AK. Commentary: DNA aneuploidy in early breast cancer. Breast Diseases 3:265, 1996.12. El-Naggar AK. Commentary: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and

other clinicopathologic variables. Breast Diseases 3:252-253, 1996.13. Austin JR, El-Naggar AK, Goepfert H. Thyroid Cancers II: Medullary, Anaplastic, Lymphoma, Sarcoma, Squamous Cell.

Ann Surg 29:611-627, 1996.14. El-Naggar AK. Commentary: Apoptosis loss and bcl-2 expression: Key determinants of lymph node metastases in T1

breast cancer. Breast Diseases 8:228-229, 1997.15. El-Naggar AK. Commentary: DNA analysis and S-phase fraction determination by flow cytometric analysis of infiltrating

lobular carcinoma of the breast. Breast Diseases 8:136-137, 1997.16. El-Naggar AK. Commentary: Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytomeetric

DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Breast Disease 8:34-35, 1997.17. El-Naggar AK. Commentary: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast

cancer. Breast Diseases 7:369-370, 1997.18. El-Naggar AK. Commentary: Prognostic value of quantitative cytometry in a series of 415 T1T2/NoN1/M0 breast

cancer patients: Preliminary report. Breast Disease:8135-8136, 1997.19. El-Naggar AK. Commentary: Imprinting in solid tumors: Cause of consequence? Advances in Anatomic Pathology

3:173-175, 1997.20. Batsakis JG, El-Naggar AK. Ewing's sarcoma and primitive neuroectodermal tumors: Cytogenetic cynosures seeking a

common histogenesis. Advances in Anatomic Pathology 4:207-220, 1997.21. El-Naggar AK. Commentary: Apoptosis of BAX and bcl-2 expression in p53 immunopositive breast cancers. Breast

Diseases 8:332, 1998.22. El-Naggar AK. Commentary: Expression of Bcl-2 protein in human primary breast carcinomas and its correlation with

multifocality, histopathological types and prognosis. Breast Diseases 9:63-64, 1998.23. El-Naggar AK, Vielh P. Commentary: Patterns of DNA ploidy and S-phase fraction associated with breast cancer

survival in blacks and whites. Breast Diseases 8:346-347, 1998.24. El-Naggar AK. Commentary: Prognostic implications of different cell cycle analysis models of flow cytometric DNA

histograms of 1,301 breast cancer patients; Results from the multicenter morphometric mammary carcinoma project(MMMCP). Breast Diseases 9:58-59, 1998.

25. El-Naggar AK. Commentary: Correlation between the expression of apoptosis-related Bcl-2 and p53 oncoproteins andthe carcinogenesis and progression of breast carcinoma. Breast Diseases 9:280, 1998.

26. El-Naggar AK. Commentary: Mitosin (a new proliferation markers) correlates with clinical outcome in node-negativebreast cancer. Breast Diseases 3:270-271, 1998.

27. El-Naggar AK. Commentary: Prognostic value of DNA ploidy using flow cytometry in 1,301 breast patients: Results ofthe prospective multicenter morphometric mammary carcinoma project. Breast Diseases 9:56-57, 1998.

28. El-Naggar AK, Klijanienko J. Advances in clinical investigations of salivary gland tumorigenesis. Ann Pathol 19:19-22,1999.

29. El-Naggar AK. Commentary: Cytogenetic abnormalities of primary breast carcinoma: Comparative analysis offluorescence in-situ hybridization (FISH) and flow cytometry. Breast Disease 2:162, 1999.

30. El-Naggar AK. Commentary: Diagnostic molecular pathology comes of age. Adv Anat Pathol 6:324-346, 1999.31. Batsakis JG, El-Naggar AK. Commentary: Myoepithelium in salivary and mammary neoplasms is host-friendly. Adv

Anat Pathol 6:218-226, 1999.32. El-Naggar AK. Commentary: Decreased apoptosis in non-involved tissue from cancer-containing breast. Breast

Diseases 2:163, 1999.33. El-Naggar AK, Benedict WF. Commentary: Retinoblastoma (RB1) gene product expression in breast carcinoma:

Correlation with Ki-67 growth fraction and biopathological profile. Breast Disease 2:163, 1999.34. El-Naggar AK. Commentary: Different proliferative patterns characterize different pre-invasive breast lesions. Breast

Diseases 11:52, 2000.35. El-Naggar AK. Commentary: Predictive value of flow cytometry for metastatic potential in breast cancer. Breast

Diseases 10:437, 2000.36. El-Naggar AK. Commentary: CD34, CD117, and actin expression in phyllodes tumor of the breast. Breast Diseases

12:299, 2001.37. El-Naggar AK. Commentary: Strong correlation between results of fluorescent in-situ hybridization and

immunohistochemistry for the assessment of the ERBBS (HER-2/neu) gene status in breast carcinoma. BreastDiseases 12:299, 2001.

38. El-Naggar AK. Commentary: c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidenceof a link between bck-2 protein over-expression and a lower risk of metastasis and death in operable patients. BreastDiseases 11:399, 2001.

39. El-Naggar Ak. Commentary: Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the

CV Output


breast. Breast Diseases 12:178, 2001.40. El-Naggar AK. Commentary: Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node

negative breast carcinoma randomized in a control trial: Multivariate analysis with Ki-67 index, mitotic count, andmicrovessel density. Breast Diseases 12:179, 2001.

41. El-Naggar AK. Commentary: Prognostic significance of p27 (KIP1) expression in resected non-small cell lung cancers: Analysis in combination with expression of p16 (INK4A), pRB and p53. J Surg Oncol 81:184, 2002.

42. Batsakis JG, Medeiros JL, Luna MA, El-Naggar AK. Plasma cell dyscrasias and the head and neck. Ann Diagn Pathol6:129-140, 2002.

43. El-Naggar AK. Commentary: Clear cell hidradenoma of the skin-a third tumor type with a t(11;19) associated TORC1-MAML2 gene fusion; Genes Chromosomes Cancer 2005;43:202-205. Adv Anat Pathology 13:80-82, 2006.

44. El-Naggar AK. Commentary: Clinicopathology features and long-term outcome of 293 phyllodes tumours of the breast.Breast Disease 19:144-145, 2008.

45. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M. Highly prevalent geneticalterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinasepathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106-3116, 2008. e-Pub 5/2008.

46. Ramdas L, Giri U, Ashorn CL, Coombes KR, El-Naggar A, Ang KK, Story MD. miRNA expression profiles in head andneck squamous cell carcinoma and adjacent normal tissue. Head Neck. e-Pub 3/2009.

47. Bell D, Kupferman ME, Williams MD, Rashid A, El-Naggar AK. Primary colonic-type adenocarcinoma of the base of thetongue: a previously unreported phenotype. Hum Pathol. e-Pub 8/2009.

48. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM,Mao L. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oralcancer in patients with leukoplakia. Clin Cancer Res 15(19):6284-91, 10/2009. e-Pub 9/2009. PMCID: PMC2756317.

49. El-Naggar AK, Kaye FJ, Shirazi Y, Gutkind JS, Forastiere AA. Meeting report--the NIDCR 2(nd) Salivary Gland TumorMeeting, November 2008. Head Neck 31(12):1542-3, 12/2009.

50. El-Naggar AK, Hopper C, Upile T, Jerjes W. Head & Neck Oncology: purpose, scope and goals-charting the future.Head Neck Oncol 1:1, 2009.

51. Anzick SL, Chen WD, Park Y, Meltzer P, Bell D, El-Naggar AK, Kaye FJ. Unfavorable prognosis of CRTC1-MAML2positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosomes Cancer 49(1):59-69, 1/2010. PMCID:PMC2783528.

52. Moskaluk CA, Frierson HF, El-Naggar AK, Futreal PA. C-kit gene mutations in adenoid cystic carcinoma are rare. ModPathol 23(6):905-6; author reply 906-7, 6/2010.

53. Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C. Mammalian target of rapamycin-dependent acinar cellneoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.Cancer Res 70(22):9143-52, 11/2010. e-Pub 11/2010.

54. Bell D, Roberts D, Karpowicz M, Hanna EY, Weber RS, El-Naggar AK. Clinical significance of Myb protein anddownstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther 12(7):569-73, 10/2011. e-Pub10/2011. PMCID: PMC3218383.

55. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guidefor interpretative relevance and consistency. Head Neck 34(4):459-61, 4/2012. e-Pub 12/2011.

Other ArticlesN/A

AbstractsN/A

Book Chapters1. El-Naggar AK. Secondary Tumors of the Larynx. In: In Laryngeal Neoplasms, 1995.2. Steck K, El-Naggar AK. In Flow Cytometry Protocols. In: Simultaneous DNA/RNA analysis of solid and hematoreticular

malignancies. 91, Methods Mol Biol. Ed(s) Jaroszeski MJ, Heller R. Humana Press 1997, 167-179, 1998.3. Steck K, El-Naggar AK. In flow Cytometry Protocols. In: Solid tumors DNA solid tumors DNA ploidy analysis. 91,

Methods Mol Biol. Ed(s) Jaroszeski MJ, Heller R. Humana Press 1997, 181-195, 1998.4. El-Naggar AK. In head and neck recertification. In: Contemporary classification of salivary gland tumor, American Board

of Otolaryngology. American Board of Otolaryngology, 1998.5. Mao L, El-Naggar AK. Molecular changes in the multistage pathogenesis of head and neck cancer in molecular

pathology of early cancer. Srivastava. S., Henson, D.E., and Gazdar . A. (ed), IOS press. . In: Amsterdam, 189-206,1999.

6. Mao L, El-Naggar AK. Molecular changes in the multistage pathologenesis of head and neck cance. In: In MolecularPatholog of Early Cancer. Ed(s) Srivastave S, Henson DE, Gazdar A. IOS Press: Amsterdam, 189-206, 1999.

7. El-Naggar AK. Diagnostic Surgical Pathology of the Head and Neck. In: .. Ed(s) Gnepp DR. W.B. Saunders Co:Philadelphia, 888, 2000.

8. El-Naggar AK. Metastasis of the larynx. In: In Diseases of the Larynx. Ed(s) Ferlito. Arnold, 2000.

CV Output


9. El-Naggar AK. Concurrent flow cytometric analysis of DNA and RNA. In: Methods Molecular Biologic. 263, Methods MolBiol. Human Press, 371-384, 2004.

10. El-Naggar AK, Vielh P. Solid tumor DNA content analysis. In: Methods Molecular Biologic. 263. Human Press, 355-370,2004.

Books (edited and written)N/A

Letters to the Editor1. Corkill, Sneige N, Fanning T, El-Naggar AK. Intracystic papillary carcinoma of the breast. Letter to the editor. . Am J

Clin Pathol 95:901, 1991.2. Ligato S, El-Naggar AK, Cleary KR, Manning J. Rectal plamacytoma (Letter to the Editor). Arch Pathol Lab Med

120:1084-1085, 1996.3. El-Naggar AK. Molecular alterations in salivary gland tumor. Surg Path 22:1164-1165, 1998.4. El-Naggar AK. Letter to the Editor: Pleomorphic adenoma. Am J Surg Pathol 22:772-773, 1999.

Manuals, Teaching Aids, Other Teaching PublicationsN/A

Other PublicationsN/A

EDITORIAL AND REVIEW ACTIVITIESEditor/Service on Editorial Board(s)

Associate Editor, Oncology Reports, 1994-1996

Associate Editor, Advances in Surgical Pathology, 1994-present

Associate Editor, Cancer Molecular Biology, 1995-present

Associate Editor, American Journal of Surgical Pathology, 1996-present

Associate Editor, Diagnostic Cytopathology, section editor, Molecular Biology, 1998-2001

Associate Editor, Breast Diseases, 1998-2005

Associate Editor, International Journal of Oncology, 1998-present

Associate Editor, Oral Oncology, 1998-present

Associate Editor, Clinical Cancer Research, 1999-present

Associate Editor, Head and Neck, 1999-present

Associate Editor, Archives of Pathology and Laboratory Medicine, 2005-present

Associate Editor, Human Pathology, 2006-present

Associate Editor, Head and Neck Pathology, 2007-2009

Editor-in-chief, Head and Neck Oncology Journal, 2008-present

Associate Editor, The Oral Pathology Journal, 2008-present

Associate Editor, Cancer Prevention Research, 2009-present

Associate Editor, Cancer Reports, 2011-present

Associate Editor, ENT Pathology, 2011-present

Member of Editorial Review BoardN/A

Journal ReviewerReviewer, Journal of Oral Pathology and Medicine, 2007

Modern Pathology

Annals of Otolaryngology and Otology

Annals of Surgical Oncology

Breast Cancer Treatment

British Journal of Cancer

Cancer

Cancer Research

CV Output


Critical reviews in Oncology/Hematology

Gene

Genes, Chromosomes and Cancer

International Journal of Cancer

Journal of Pathology

Laryngoscope

The American Journal of Clinical Pathology

The American Journal of Pathology

The European Journal of Cancer

Other Editorial and Review ActivitiesN/A

TEACHINGTeaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal TeachingCourses Taught

Instructor, Tumor Heterogeneity and MetastasisSpring, 1/2008-present

Training ProgramsInstructor, Pathology, Instructor, The University of Texas, M.D. Anderson Hospital and Tumor Institute

1987-1988

Other Formal TeachingAssistant Professor, Pathology

1988-1991

Associate Professor, Pathology1991-1995

Professor of Pathology and Head and Neck Surgery, Pathology1995-present

Supervisory TeachingCommittees

Advisory CommitteesN/A

Supervisory CommitteesYoli Sanchaz, 1995-1997

Steve Lott, 1997-2001

Hariya Pannu, 1999-present

Leslie Rogers, 2002-2004

Jay Herman, 2004-2006

Yasmine A. Valentin, 2004

Chris Holsinger, M.D., 2006-present

Examining CommitteesN/A

Direct SupervisionUndergraduate and Allied Health Students

N/A

Medical StudentsN/A

Graduate StudentsN/A

Postdoctoral Research FellowsK.J. Cho, 1994-1995

CV Output


Ben Warner, 1998-1999

Hong-Ran Choi, 2000-2002

Shinichiro Maruya, 2003-2004

Kazufumi Ohshiro, 2004-2006

Naoki Otsuki, 6/2004-6/2005

Mahitosh Mandal, M.D., Ph.D., 2005-2006

Eung Seok Lee, M.D., 4/2006-6/2007

Yamilet Tirado, M.D., 10/2006-12/2006

Yoshitsugu Mitani, M.D., 12/2008-present

Clinical Residents and FellowsMentor, Head and Neck Fellowship Program, Michelle Williams, MD, 7/2007-6/2008

Mentor, Head and Neck Fellowship Program, Diana Bell, MD, 7/2008-6/2009

Mentor, Head and Neck Fellowship Program, Matthew Karpowicz, MD, 7/2009-6/2010

Mentor, Head and Neck Fellowship Program, Hanadi Fatani, MD, 7/2010-6/2011

Mentor, Head and Neck Fellowship Program, David Tasso, MD, 7/2011-present

Other Supervisory TeachingP. Parichatikanod, 1987-1989

Jose Rodriquez-Perlato, 1990-1991

Rosario Carrillo, 1990-1991

Troy Callender, 1991-1992

Carla Giannoni, 1992-1993

Madelene Flatz, Postdoctoral Research Fellows, 1992-1993

Abdulla Aydin, Postdoctoral Research Fellows, 1993-1994

Ana Felix, Postdoctoral Research Fellows, 1994-1995

Maryam Bakhshandeh, September, Postdoctoral Research Fellows, 1994-1996

Ying-Tai Jin, Postdoctoral Research Fellows, 1996-1997

Jesus Solla, Postdoctoral Research Fellows, 1997-1998

Aurora Romero, Postdoctoral Research Fellows, 1998-3/1999

Guliz Barkan, Postdoctoral Research Fellows, 2001

Irene E. Erana-Rojas, Postdoctoral Research Fellows, 2002

Bent Corden, M.D., 7/2006-9/2006

Teaching Outside Current InstitutionFormal Teaching

Courses TaughtN/A

Training ProgramsClinical Pathology, Ein-Shams Medical School

1975-1980

Teaching fellow, Case Western Reserve University, School of Medicine1982-1986

Other Formal TeachingN/A

Supervisory TeachingCommittees

Advisory CommitteesN/A

Supervisory CommitteesN/A

CV Output


Examining CommitteesN/A

Direct SupervisionUndergraduate and Allied Health Students

N/A

Medical StudentsN/A

Graduate StudentsN/A

Postdoctoral Research FellowsN/A

Clinical Residents and FellowsN/A

Other Supervisory TeachingN/A

CONFERENCES AND SYMPOSIAOrganization of Conferences/Symposia (Include chairing session)

N/A

Presentations at National or International ConferencesInvited

N/A

Other, Including Scientific ExhibitionsN/A

Seminar Invitations from Other InstitutionsSalivary gland neoplasms -- slide seminar, Cairo University, Cairo, Egypt, 2/1989

Surgical Pathology slide seminar, Department of Pathology - Ein-Shams University, Cairo, Egypt, 11/1990

Head and Neck slide seminar, International Academy of Pathology, Buenos Aires, Argentina, 4/1991

Head and Neck Pathology slide seminar, Institute of Pathology, Case Western Reserve Unive, Cleveland, OH, 5/1991

Slide seminar, unusual cases, Mexican Society of Surgical Pathologist, Mexico City, Mexico, 1992

Molecular Biology, Workshop (LOH, SSCP, RFLP and Microsatellite Analysis), Cairo, Egypt, 11/1995

Surgical Pathology -- selected cases, Department of Pathology, Ein-Shams University, Cairo, Egypt, 11/1995

Head and Neck Research Direction Workshop, Progression Break out Group-Leader, Bethesda, MD, 2/1999

Slide Seminar in Head and Neck Tumors, The University of Florida, Jacksonville, FL, 8/2000

ENT Seminar, Co-Chair at the 27th European Congress of Cytology, Lillehammer, Norway, 9/16/2000

In-situ hybridization technologies in clinical practice, The 3rd International FASBMB Congress, Cairo, Egypt, 11/2000

Microsatellites markers – pitfalls and guidelines, The 3rd International FASBMB Congress, Cairo, Egypt, 11/2000

Pathology Templates, Head and Neck Intergroup Meeting, Rockville, MD, 12/7/2001

SPORE, 10th SPORE Investigators Workshop, Chantilly, VA, 7/13/2002

Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, McLean, VA, 10/9/2002

SWOG, Southwest Oncology Group, San Diego, CA, 4/2003

HN Intergroup, Head and Neck Intergroup Meeting, Rockville, MD, 5/22/2003

SPORE, 11th SPORE Investigators Workshop, Baltimore, MD, 7/8/2003

Pathology & Genetics of Head and Neck Tumours, Lyon , France, 7/16/2003

WHO, WHO Classification of Head and Neck Tumours, Lyon, France, 7/16/2003

SWOG, Southwest Oncology Group, Seattle, WA, 10/2003

RTOG, Radiation Therapy Oncology Group Meeting, New Orleans, LA, 1/2004

ACSOG, American College of Surgeons Oncology Group, Miami, FL, 1/8/2004

CV Output


SPORE, Head and Neck InterSPORE Meeting, Orlando, FL, 3/29/2004

SWOG, Southwest Oncology Group Meeting, Huntington Beach, CA, 4/2004

ACOSOG, American College of Surgeons Oncology Group, Chicago, IL, 6/2004

RTOG, Radiation Therapy Oncology Group Meeting, Washington, DC, 6/2004

SPORE, 12TH SPORE Investigators Workshop, Baltimore, MD, 7/10/2004

HN Intergroup, Head and Neck Intergroup Meeting, Rockville, MD, 8/8/2004

SWOG, Southwest Oncology Group Meeting, Kansas City, MO, 10/2004

SWOG, SWOG, Semiannula Meeting, Kansas City, MO, 10/2004

HN Intergroup, Head and Neck Intergroup Meeting, Bethesda, MD, 12/17/2004

ACOSOG, American College of Surgeons Oncology, San Antonio, TX, 1/2005

RTOG, Radiation Therapy Oncology Group Meeting, Phoenix, AZ, 1/2005

RTOG, Radiation Therapy Oncology Group Meeting, Philadelphia, PA, 6/2005

SPORE, 13th SPORE Investigators Workshop, Washington, DC, 7/2005

RTOG, Radiation Therapy Oncology Group, Miami Beach, FL, 1/2006

SWOG, Southwest Oncology Group Meeting, Salt Lake City, UT, 4/2006

RTOG, Radiation Therapy Oncology Group, Toronto, Canada, 6/2006

SPORE, 14th SPORE Investigators Workshop, Baltimore, MD, 7/2006

SWOG, Southwest Oncology Group Meeting, Seattle, WA, 10/2006

RTOG, Radiation Therapy Oncology Group, Tampa, FL, 2/2007

RTOG, Radiation Therapy Oncology Group, Philadelphia, PA, 6/2007

PhenoPath, IRX Therapeutic, Seattle, WA, 7/2007



PhenoPath, IRX Therapeutic, Seattle, WA, 9/2007

HN Intergroup, Head and neck Intergroup Meeting, Bethesda, MD, 11/30/2007

HNSC, Head and Neck Steering Committee Meeting, Rockville, MD, 12/3/2007

RTOG, Radiation Therapy Oncology Group, San Diego, CA, 1/2008

ACRIN, American College of Radiology Imaging Network, Washington, DC, 10/2008

HPV, Squamous Cell Head and Neck Cancer and the Human Papillomavirus, Washington, DC, 11/2008

RTOG Meeting, American College of Radiology, Chicago, IL, 6/26/2009

RDCRN 1st Steering Committee Meeting, NIH/NCI, Bethesda, MD, 9/30/2009

ACC Sequencing Meeting, American Cytogenetics Conference, Hinxton, United Kingdom, 3/1/2010

MYB-NFIB fusion gene and MYB transcript and protein expression in salivary adenoid cystic carcinoma: incidence andassociation, The Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 3/2/2010

RTOG Meeting, American College of Radiology, Philadelphia, PA, 6/18/2010

AMEGN, Applied Molecular Genetics Committee, Vancouver, British Columbia, 9/11/2010

RDCRN Steering Committee Meeting, NIH/NCI, Washington, DC, 9/22/2010

ACRIN Meeting, American College of Radiology Imaging Network, Arlington, VA, 9/30/2010

RTOG Head & Neck Subcommittee Meeting, American College of Radiology, San Diego, CA, 1/14/2011

RTOG Head & Neck Subcommittee Meeting, American College of Radiology, Philadelphia, PA, 6/17/2011

ACRIN Meeting, American College of Radiology Imaging Network, Arlington, VA, 9/22/2011

RTOG January Symposium, American College of Radiology, Atlanta, GA, 1/19/2012

RTOG Head & Neck Retreat and Pipeline Meeting, American College of Radiology, Philadelphia, PA, 2/2/2012

RTOG Head & Neck Surgical Subcommittee Meeting, American College of Radiology, Philadelphia, PA, 6/15/2012

CV Output


AEN Larynx / AEN Squamous Tumorigenesis, Venezuelan Oncology Congress, Sociedad Venezolana De Oncologia,Caracas, Venezuela, 7/5/2012

Tumor Board: Pharynx/Larynx, 8th Intl. Confr. on Head & Neck Cancer, ICHNC, Toronto, Canada, Canada, 7/21/2012

TCGA Head & Neck Workshop, NIH/NCI, Chapel Hill, NC, 9/18/2012

RDCRN Steering Committee Meeting, NIH/NCI, Rockville, MD, 4/30/2013

RDCRN Steering Committee Meeting, NIH/NCI, Rockville, MD, 10/1/2013

ACRIN Meeting, American College of Radiology Imaging Network, Hollywood, FL, 11/15/2013

Lectureships and Visiting ProfessorshipsClinical Application of Flow Cytometry, Mexican Society of Pathology Annual Meeting, Saltio, Mexico, 5/1988

Multiparameter Flow Cytometric analysis of Solid Human Tumor, Dako Corporation, Santa Barbara, CA, 5/1989

Flow Cytometry in Contemporary Clinical Oncology, The 50th Anniversary of the Mexican Cancer Institute, Mexico City,Mexico, 10/1989

Cell Kinetics in the Evaluation of Biological Progression of Solid Malignant Tumor, University of Kansas, Department ofRadiotherapy, Kansas City, KS, 12/1989

Acridine Orange Flow Cytometry in the Assessment of Human Neoplasia, The San Antonio Flow Cytometry Forum Meeting,The University of Texas, San Antonio, TX, 11/1990

Interphase Cytogenetics in Solid Tumor, Visiting - Professor, King Fiasal Specialist Hospital, Riyadh, Saudi Arabia, 2/1991

DNA Content Analysis by Flow Cytometry Application and Limitations, The Costa Rican Society of Pathologists AnnualMeeting, San Jose, Costa Rica, 5/1991

Clinical Implication of DNA Content Heterogeneity in Solid Tumor, Key Note Speaker, 1st International Meeting onMolecular Biology of Cancer, Cairo, Egypt, 1992

Molecular Genetics in Pathology, The Venezuelan Society of Pathologists Annual Meeting, Caracas, Venezuela, 12/1992

Flow Cytometric DNA Content and Proliferation markers in Modern Surgical Pathology, Annual Meeting - Latin AmericanAssociation of Pathologists, San Jose, Costa Rica, 1993

Simultaneous Analysis of DNA and RNA content Analysis in the Evaluation of Hematoreticular and Solid Neoplasm’s, TheSilver Jubilee - Ein-Shams Medical School, Cairo, Egypt, 1993

Pathological Evaluation of Salivary Gland Neoplasm’s, Annual Meeting - South American Society of Otolaryngology, Juarez,Mexico, 5/1993

Pre-Malignant Lesions of Head and Neck Region, The Venezuelan Society of Oral Medicine, Caracas, Venezuela, 5/1993

DNA Analyses by Flow Cytometry in the Assessment of Ovarian Carcinoma, 2nd International Meeting on MolecularBiology of Cancer, Cairo, Egypt, 11/1993

Cell Proliferation and Death by Flow Cytometry in Solid Tumors, Rocky Mountain Flow Cytometry Symposium, Angel Fire,NM, 5/1994

Molecular Genetics in Surgical Pathology of Solid Tumor, Annual Meeting of the Mexican Association of Pathologists,Morelia, Mexico, 5/1994

Multiparameter Flow Cytometry in Solid and Lymphoreticular Malignancy Evaluation, Mexican Society of Pathology,Monterey, Mexico, 9/1994

Oncogenes and Tumor Suppressor Genes in Head and Neck Squamous Carcinoma, The 3rd International Meeting of theMediterranean Society of Tumor Markers, Athens, Greece, 10/1994

Sequential Genomic Alterations Using Microsatellite Markers in Pre-Invasive and Invasive Head and Neck SquamousCarcinoma, Institute Curie, Paris, France, 11/1994

Sequential p53 Mutations in Pre-Invasive and Invasive Head and Neck Squamous Carcinoma, 1st International Meeting onGenetics in Head and Neck Cancer, Sao Paulo, Brazil, 3/1995

Simultaneous DNA and RNA flow Cytometric Analysis in Breast Carcinoma, Special Lecture, Hospital Albert EinsteinInsraelita, Sao Paulo, Brazil, 3/1995

Flow Cytometric Measurements of Apoptosis and Bcl-2 in Solid Malignancies: Clinical Implications, San Antonio FlowCytometry Society Meeting, San Antonio, TX, 5/1995

Biological Significance of Apoptosis and Bcl-2 Flow Cytometric Analysis in Human Neoplasia, The 8th Annual FlowCytometry Forum, San Antonio, TX, 12/1995

Bcl-2 and Apoptosis Analysis by Flow Cytometry in the Assessment of Mammary Carcinoma, Institute Curie, Paris, France,

CV Output


1/1996

Clinical Relevance of Concurrent Bcl-2 and Apoptosis Analysis in Solid Tumor, Dako Corporation - Internationa SalesMeeting, Santa Barbara, CA, 1/1996

Molecular Alterations in Head and Neck Tumorigenesis, International Symposium on Advances in Head and neck Cancer,Kiel, Germany, 1/1996

Bcl-2 and Apoptosis Measurement in Solid Tumor, Oncology and tumor Marker Unit - Zagazig School of Medicine, Egypt,3/15/1996

FISH Technology, Current and Future Prospects, Vysis Corporation, Downers Grove, IL, 6/1996

Surgical Pathology and Translational Research, Loyola University, Pathology, Chicago, IL, 8/6/1996

A) Potential Diagnostic and Prognostic Implication of oncogenes and Tumor Suppressor Genes in Squamous CellTumorigenesis, B) Neuroendocrine Carcinoma of the Lung, The 5th Marmara Medical Days, Istanbul, Turkey, 9/1996

Genetic Alteration in Head and Neck Squamous Oncogenesis, Grand Round, University of Texas at Houston MedicalSchool, Houston, TX, 10/9/1996

Genetic Alterations and Molecular Biology in Human Neoplasia, National Meeting of the School of Medicine of theUniversity of Nuevo Leon, Monterey, Mexico, 10/17/1996

Cell Proliferation and Death in the Biology of Solid Tumors, Oncor Corporation, Gatherberg, MD, 3/1997

Genetic and Epigenetic Alterations Leading to the Abrogation of p16 in Head and Neck Squamous Tumorigenesis, CurieInstitute, Paris, France, 6/10/1997

Sequential Genetic Alterations at Microsatellite Loci in the Development of Head and Neck Squamous Carcinoma, CurieInstitute, Paris, France, 7/8/1997

Proliferation and Apoptosis in the Assessment of Solid Tumor Dynamics, University of Pamplona, Pamplona, Spain,7/11/1997

Microsatellite markers as a tool in the analysis of head and neck premalignant squamous lesions, University of Barcelona,Barcelona, Spain, 7/17/1997

Molecular Genetic Screening of Salivary Gland Tumors: Putative Chromosomal Regions Associated with Their Developmentand Progression, Curie Institute, Paris, France, 8/12/1997

Apoptosis and Viability Genes in the Evaluation of Mammary Carcinoma, Dako’s Corporation - New Tools andTechnologies in Immunohistochemically Molecular Biology, Houston, TX, 9/12/1997

Epigenetic Alterations Associated Head and Neck Tumorigenesis: Cause or Consequence, International Symposium onMetastases in Head and Neck Cancer, Kiel, Germany, 1/1998

Fine Mapping of Chromosome 8p Regions Involved in Early and Invasive Head and Neck Squamous Carcinoma, CurieInstitute, Paris, France, 5/26/1998

Imprinting Relaxation of H19 and IgF2 Genes on Chromosome 11p15 in Primary Head and Neck Squamous Carcinoma,Curie Institute, Paris, France, 6/2/1998

Laser Capture Microdissection in Molecular Genetic Analysis, Curie Institute, Paris, France, 7/7/1998

p16 Inactivation in Head and Neck Squamous Carcinoma, The 5th Research Workshop on the Biology, Prevention andTreatment of Head and Neck, McLean, VA, 8/1998

Applications of laser Capture Microdissection in Molecular Genetic Analysis of Solid Tumors, 5'e Etage de La Polycliniquede 1'Institut J. Bordet Brussel, Brussel, Belgium, 8/20/1998

Laser Capture Microdissection in Molecular Genetic Analysis of Cancer, InterLab 98 International Meeting, Cairo, Egypt,10/18/1998

Molecular Pathology and Cancer Genomics: Concept and Prospects, Visiting Professor, Medical College of Georgia,Pathology, Augusta, GA, 1/11/1999

Phenotypic Biomarkers and Genetic Features in Thoracic Cancers, Lung Cancer Workshop - Metropolitan FlorenceNightingale Cancer Center, Istanbul, Turkey, 6/1999

1) "Genomics and Cancer Biology" 2) "Epigenetic Modification of p16 Suppressor Gene in Head and Neck SquamousTumorigenesis, King Faisal Hospital and Research Center, Riyadh, Saudi Arabia, 2/2000

Pathobiology and Molecular Genetics of Salivary Gland Neoplasms, Texas Medical School - Grand Round, OtolaryngologyHead and Neck Surgery, Houston, TX, 4/6/2000

Gene Expression Analysis of Upper Respiratory Tract Squamous Tumorigenesis, Vysis Corporation, Downers Grove, IL,

CV Output


5/2000

Genetic and Epigenetic Alterations in Head and Neck Squamous Tumorigenesis: Diagnostic and Therapeutic Prospects,University of Florida, Pathology, Jacksonville, FL, 8/4/2000

Biomarkers Analysis and Challenges, NCI, Washington , DC, 9/8/2000

New Technologies Applicable to Cytology, The 27th European Congress of Cytology, Lillehammer, Norway, 9/19/2000

Gene Express Analysis of Head and Neck Squamous Carcinoma, Curie Institute, Paris, France, 9/28/2000

Molecular Alterations in Pulmonary Neoplasm, University Hospital of Monterrey, Monterrey, Mexico, 10/27/2000

Microarray Technology in the Analysis of Solid Tumors: Promise and Prospects, The 3rd International FASBMB Congress,Cairo, Egypt, 11/2000

Conventional and Molecular Pathology of Laryngeal Carcinoma, Tufts University New England Medical Center, Boston ,MA, 11/4/2000

Molecular Screening of Lower Respiratory Tract Tumors, at What Cost"?, Vysis Corporation, Downers Grove, IL, 2/2001

Lung Cancer Pathology and Tissue Banking Issues, Millennium Pharmaceuticals, Cambridge, MA, 4/2001

Pearls Grand Round, M.D. Anderson Cancer Center, Houston, TX, 6/1/2001

Phenotypic and Biological Evaluation of Thyroid Tumors, The University of Texas Health Science Center (Grand Round),Houston, TX, 1/31/2002

Dissecting Head and Neck Squamous Tumorigenesis: Present status and Future Prospects, Institute – Gustane Russy,Villejuif, France, 2/5/2003

Pathologic Standardization: Promises and Challenges, Curie Institute, Paris, France, 2/6/2003

Pathologic Diagnosis of Salivary Gland Neoplasms, The University of Texas Health Science Center (Grand Round),Houston, TX, 4/3/2003

Genetic and Epigenetic Markers in Head and Neck Squamous Carcinoma Detection and Progression, Radium Hospital,Olso , Norway, 9/11/2003

Methylation Analysis of Cancer Related Genes in Head and neck Squamous Carcinoma, The 6th International Conferenceof Cancer Biolgoy, Crete, Greece, 10/2003

Squamous and Carcinoma Variants of the Head and Neck, M.D. Anderson Surgical Pathology Update 2003, Pathology,Houston, TX, 10/2003

Phenotypic and Biological Heterogeneity: Molecular Diagnostic Implications, Vanderbilt University, Nashville, TN, 12/4/2003

Biomarker Identification and Validation in HNSC: Current and Future Prospects, Emory University, Atlanta, GA, 3/18/2004

Biomarker Applications and Validations in Oral Cancer Trials: Present and Future Prospects, National Institutes of Health(NIH), Methods for Enhancing the Efficiency of Dental/Oral Health Clinical Trials, Bethesda, MD, 5/6/2004

Phenotypic Heterogeneity of Head and Neck Squamous Carcinoma: Evidence for Linear and Stochastic Molecular Linkage,The University of Texas Medical Branch at Galveston - (Grand Round), Pathology, Galveston, TX, 5/24/2004

Novel Estrogen Receptor Coactivator PELP1/MNAR Gene and ERb Expressed in Salivary Duct Adenocarcinoma: PotentialTherapeutic Targets" and gene expression screening of salivary gland neoplasms: molecular markers of potentialhistogenetic and clinical signi, 6th International Conference on Head and Neck Cancer Meeting, Washington, DC, 8/2004

Differential Methylation Status of Tumor associated Genes in Head and Neck Squamous Carcinoma: Incidence andPotential Implications, The 7th International Symposium on Molecular Medicine, Crete, Greece, 10/2004

Molecular Pathology Practice: Present and Future, The 75th Anniversary of the Institute of Pathology, Case WesternReserve University, Cleveland, OH, 10/2004

Grand Round Molecular Pathology of Head and Neck Neoplasms, The University of Oklahoma, Oklahoma City, OK,10/14/2004

Biomarkers Development and Validation in Head and Neck Trials: Pathology Role and Prospective, IGR Institurt Gustave-Roussy, Paris, France, 12/7/2004

Molecular Pathology of Sarcomas and Skull Base Tumors, The EORTC Meeting on Rare Head and Neck Tumors Meeting,Brussels, Belgium, 12/11/2004

Morphology of Head and Neck Sarcomas, The EORTC Meeting on Rare Head and Neck Meeting, Brussels, Belgium,12/11/2004

Epigenetic Alterations in Head and Neck Cancer Related Genes: Current and Future Propsects, 3rd Annual Opinion LeaderConsortium on Novel and Targeted Therapies for Head and Neck,, Cancum, Mexico, 2/2005

CV Output


Molecular Basis of Head and Neck Tumors, The University of Florida, Jacksonville, FL, 4/12/2005

Integration of Novel Diagnostic and Prognostic Markers and Traditional Factors in Routine Practice, The University of TexasHealth Science Center at Houston (Grand Round), Houston, TX, 6/2/2005

Case 4 Nasopharynx Cancer, Virtual Head and Neck Cancer Case Challenge, Chicago, IL, 9/16/2005

Molecular Markers: Diagnostic and Therapeutic Perspectives, 31st European Congress of Cytology, Paris, France, 10/2005

Pathology Assessment of Salivary Gland Tumors" "Tissue and Fluid Materials Banking in Cancer Research: Outline forPractical Implementation" "Thyroid Cancer" "Sarcoma Lecture" Prognostics Markers and Diagnostic Dilemma in Patientswith Chemo-Radiation, Multimodality Head and Neck Cancer Care in the New Millennium, Mumbai, India, 12/2005

Overview of Head and Neck Cancer Biology, 1st Annual Multidisciplinary Symposium of Head and Neck Cancer,Philadelphia, PA, 12/2/2005

Comparative Saliva Proteomics: Potential Screening Markers for Head and Neck Squamous Carcinoma, US and CanadianAcademy of Pathology, Atlanta, GA, 2/2006

Molecular Biology of Squamous Cell Carcinoma, Pathology of the 21st Century, Houston, TX, 5/2006

Analytical Effect of Saliva Processing on Proteomic Screening for Biomarkers in Head and Neck Squamous Carcinoma,American Head and Neck Society (AHNS), Chicago, IL, 8/2006

Follicular Carcinoma of the Thyroid: Pathology Controversies, MDACC-Institut Gustave Roussy International ScientificSymposium, Paris, France, 9/2006

Molecular Diagnosis of Head and Neck Tumors and Molecular Biology of Squamous Cell Carcinoma, US and CanadianAcademy of Pathology, Montreal, Quebec, Canada, 9/2006

Biomarkers in Salivary Gland malignancies, 1st Workshop on Biology in Salivary Gland, Bethesda, MD, 10/2006

Overview of Head and Neck Cancer Biology, 2nd Annual Head and Neck Cancer Symposium, Philadelphia, PA, 12/2/2006

Epithelial-Mesenchymal Transition in Head and Neck Squamous Tumorigenesis, The Banburg Center, Cold Spring Harbor,NY, 2/2007

(Dr. Naqvi) Epithelioid Hemangioendothelioma of the Head and Neck: A clinicopathologic and Immunohistochemical Study,US and Canadian Academy of Pathology, San Diego, CA, 3/2007

(Dr. Williams) DNA Methylation: A Comparative Study of Methodologies in Salivary Gland Neoplasia, US and CanadianAcademy of Pathology, San Diego, CA, 3/2007

(Dr. Williams) Epithelial-Mesenchymal Transformation and Invasion in Head and Neck Squamous Carcinoma, US andCanadian Academy of Pathology, San Diego, CA, 3/2007

Molecular Biology of Squamous Cell Carcinoma, Egypt Lecture, Cairo, Egypt, 4/2007

No Presentation, American Head and Neck Society Meeting, San Diego, CA, 4/2007

Unknown Conference, Institut Gustave Roussy (IGR), Paris, France, 4/2007

Molecular Aspects of Salivary Gland Neoplasia, 21st Pathology Century Conference, Houston, TX, 5/2007

Pathology and Tissue Banking, 3rd Annual Sister Institutions Meeting, Houston, TX, 6/2007

Epithelial-Mesenchymal Transition in Head and Neck Squamous Tumorigenesis, 12th World Congress, Creta, Greece,10/11/2007

Advances in Molecular Genetics and Biomarkers of Salivary Neoplasia, 2nd International Congress of Salivary Gland,Philadelphia, PA, 10/18/2007

Pathology and Tissue Banking, Head and Neck Surgery Department Research Retreat, Head and Neck Surgery,Woodland, TX, 11/30/2007

1) Phenotypic Manifestations of Head and Neck Sarcomas; 2) Pathology of Sinonasal Cancer; 3) Tissue and MaterialsBanking; 4) Molecular Diagnosis of Head and Neck Tumors; 5) Slides Seminar; 6) Histogenesis, Pathology and Biology ofSalivary Gland Tumors and 7) Thyroid cancer, King Fahad Medical University, Pathology, Saudi Arabia, 2/2008

(Dr. Diana Bell) Deletion of Chromosome 1p32-p36 Region is the Most Frequent Aberration and a Poor OutcomePredicator in Adenoid Cystic Carcinoma of the Salivary Gland, US and Canadian Academy of Pathology, Denver, CO,3/4/2008

HNSC Phenotypic and Molecular Heterogeneity, MDACC: Surgical Pathology Conference, Pathology, Houston, TX,4/8/2008

Hormonal and Growth Factors Studies in Salivary Duct Carcinoma, MDACC and IGR Workshop, Houston, TX, 4/11/2008

CV Output


Hormonal and Growth Factors Studies in Salivary Duct Carcinoma, The Adenoid Cystic Carcinoma Research Foundation(ACCRF) Scientific Forum at the Salk Institute, San Diego, CA, 4/14/2008

Head and Neck Banking and Pathology of Salivary Gland Tumors, ACC Camargo Sister Institution Meeting, San Paulo,Brazil, 5/2008

Salivary Gland Neoplasms "Current Status of Biomarkers in Clinical Trials of Salivary Carcinoma," MDACC: MultidisciplinaryHead and Neck Research Conference, Head and Neck, Houston, TX, 5/7/2008

Molecular Alterations in Head and Neck Tumorigenesis: Diagnostic and Biological Implication, ACC Camargo SisterInstitution Meeting, San Paulo, Brazil, 7/2008

Nuts and Bolts of Tissue Banking and Pathology and Molecular Biomarkers in the Assessment of Salivary Gland Cancer,7th International Conference of Head and Neck Cancer, San Francisco, CA, 7/2008

Salivary Gland Tumor, MDACC: Head and Neck Surgical Pathology Conference, Head and Neck, Houston, TX, 9/2/2008

EMT in Head and Neck Squamous Carcinoma, Eight International Conference of Anticancer Research, Kos, Greece,10/2008

Pathobiology of Head and Neck Squamous Tumorigenesis, International Academy of Pathology Symposium, Athens,Greece, 10/2008

1) Molecular Pathology of Salivary Gland Tumours, 2) Molecular Pathology of HNS Tumorigenesis: Progress and Promiseand 3) Slides Seminar, Pathology of the Head and Neck Region, Lisbon, Portugal, 11/2008

State of Salivary Gland T umor Biorepository, Workshop on Salivary Gland Tumor Research: Current Status and FutureDirections, NIH/NCI, Bethesda, MD, 11/2008

1) Salivary Gland Tumor, 2) Controversial Topics in Head and Neck Pathology, 3) Slide Seminar, 4) Thyroid Cancer and 5)Skull Base Tumor, King Fahad Medical University, Saudi Arabia, 1/2009

Molecular and Biomarker Role in Multidisplannary Management of Head and Neck Squamous Carcinoma: Current Statusand Future Perspectives, Eignth Shaukat Khanum Memorial Cancer Symposium, Lahore, Pakistan, 2/2009

Histopathologic and Phenotypic Assessment in the Development and Valdation of Optical Diagnostic Devices for Head andNeck Mucosal Lesions, 1st Scientific Meeting of HNODS, London, England, 3/14/2009

14th World Congress on Advances in Oncology, Spandidos, Loutraki, Greece, 10/9/2009

ACCRF's Scientific Advisory Board, Adenoid Cystic Carcinoma Research Foundation, Boston, MA, 11/1/2009

King Fahad Medical City Conference, Academic & Training Affairs, Riyadh, Saudi Arabia, 2/1/2010

Squamous Cell Carcinoma in Fanconi Patients, American Head and Neck Society, Chicago, IL, 4/7/2010

Hayes Martin Lecture, MDACC: Head and Neck Surgical Pathology Conference, Houston, TX, 4/28/2010

14th International Thyroid Congress, Palais des Congrès, Paris, France, 9/13/2010

Annual Meeting of AAO - Head & Neck Surgery, American Academy of Optometry, Boston, MA, 9/25/2010

AHNS 2010 Research Workshop on Biology Prevention & Treatment of Head & Neck Cancer, American Head & NeckSociety, Arlington, VA, 10/27/2010

2011 Photonics West, SPIE, San Francisco, CA, 1/22/2011

Head & Neck Steering Committee Meeting 1, NIH/NCI, Rockville, MD, 4/26/2011

Otolaryngology Grand Rounds, University of San Francisco, San Francisco, CA, 5/16/2011

International Clinical Trials, NIH/NCI, Chicago, IL, 6/5/2011

Head & Neck Steering Committee Meeting 2, NIH/NCI, Rockville, MD, 9/20/2011

Clinical Trials Planning Meeting / Head & Neck Steering Committee Meeting, NIH/NCI, Washington, DC, 11/6/2011

Congress of the Arab Division, CAD, Beirut, Lebanon, 11/27/2011

Salivary Gland Conference, Hosted by Dr. Adel El-Naggar from UTMDACC, Washington, DC, 2/6/2012

ICPN Lecture, ICPN, Cairo, Egypt, 2/25/2012

Scientific Advisory Board Meeting, NIH/NCI, Chicago, IL, 3/16/2012

4th Scientific Meeting of HNODS, The Head & Neck Optical Diagnostic Society, Kissimmee, FL, 4/18/2012

2012 Head & Neck Steering Committee Meeting, NIH/NCI, Rockville, MD, 4/24/2012

3rd Annual Editor's Conference, NIH/NCI, Washington, DC, 5/29/2012

15th Annual Venezuelan Head & Neck Oncology Congress, Venezuelan Oncology Congress, Caracas, Venezuela,

CV Output


7/5/2012

8th International Conference on Head & Neck Cancer Program Committee, The American Head and Neck Society, Toronto,Canada, 7/20/2012

2012 Steering Committee Meeting, NIH/NCI, Rockville, MD, 10/1/2012

17th World Congress on Advances in Oncology on Molecular Medicine, Dr. Demetrios A. Spandidos, Crete, Greece,10/8/2012

International Pathology Symposium, Riyadh Military Hospital Organizing Committee, Riyadh, Saudi Arabia, 11/24/2012

Tumor Progression - I, Biology of Cancer Metastasis Lecture, The University of Texas M D Anderson Cancer Center,Genitourinary Medical Oncology, Houston, TX, 1/30/2013

Tumor Progression - II, Biology of Cancer Metastasis Lecture, The University of Texas M D Anderson Cancer Center,Genitourinary Medical Oncology, Houston, TX, 2/1/2013

Salivary Gland Tumors, Nagoya City Univ Graduate School of Med Sci & Med School, Nagoya, Japan, 5/21/2013

International Pathology Symposium, Riyadh Military Hospital Organizing Committee, Riyadh, Saudi Arabia, 11/23/2013

Other Presentations at State and Local ConferencesN/A

PROFESSIONAL MEMBERSHIPS/ACTIVITIESProfessional Society Activities, with Offices Held

National and InternationalInternational Head Neck Scientific Group

Member, 11/2010-present

American Association for Cancer Research (AACR)

American Association for the Advancement of Science

American College of Pathology (ACP)

American College of Surgeons

American Medical Association

American Society of Clinical Pathology (ASCP)

Arthur Purdy Stout Society

International Academy of Pathology (IAP)

International Society for Analytical Cytology (ISAC)

Local/StateTexas Medical Association

UNIQUE ACTIVITIES1. Head and Neck Surgical Oncology/Pathology Slide Conference

2. Head and Neck surgical Pathology Conference

3. Special course on usual Endocrine Neoplasia, The 6th International Head and Neck Cancer Meeting, July 2004,Washington, DC.

4. Planning Committee for the International Head and Neck Research Conference 2008

5. Organizing Committee for the NCI - Conference on Salivary Tumours DATE OF LAST CV UPDATE

2/25/2014

Documents

CURRICULUM VITAE Adel K. El-Naggar, M.D., Ph.D. · CURRICULUM VITAE Adel K. El-Naggar, M.D., Ph.D. PRESENT TITLE AND AFFILIATION Primary Appointment Professor, Department of Pathology,